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Abstract 
Total knee arthroplasty is a common elective orthopaedic procedure. The surgery itself 
causes soft tissue and bony trauma leading to a systemic response which includes 
endocrinological, immunological and haematological events. This thesis aims to 
investigate the potential association between total knee arthroplasty and such markers 
of inflammation, endothelium and coagulation.  
 
The study consisted of 4 groups; group 1 underwent an uncemented total knee 
arthroplasty; group 2 underwent a cemented total knee arthroplasty; group 3 
underwent an uncemented total knee arthroplasty but received an intra-operative 
infiltration of local anaesthetic; group 4 underwent an uncemented total knee 
arthroplasty but had a post-operative drain for 24hours. Blood sampling was undertaken 
pre-operatively and at day 1 and day 7 post-operatively for the white cell count, 
platelets, neutrophils, C-reactive protein, interleukin 6, e-selectin, soluble CD40L, 
tissue plasminogen activator, von Willebrand factor, CD40 and CD1442a. Statistical 
analysis was undertaken in the form of pair sampled t-tests between group 1 and each 
of the other three groups.  
 
Although there some significant changes in one or two of the variables between the 
groups the only variable which demonstrated a significant difference in all comparisons 
was the CD1442a count. The exact role of CD1442a is unclear but there evidence to 
suggest that it may reflect the inflammatory and thrombotic process or contribute 
directly to the ongoing atherothrombogenesis.  
 
During the statistical analysis it was noted that the majority of the variables showed no 
clear statistical difference between the groups. In chapter 7 an ANOVA / Freidman 
analysis demonstrated that all but one of the variables, the CD1442a count, showed no 
statistical difference between all four groups. This allowed all the variables to be 
collated and presented as the single largest cohort study to date demonstrating the 
effects of total knee arthroplasty on the markers of inflammation, endothelium and 
coagulation. All the variables assessed showed a statistically significant change from 
pre-operative levels to day 7 post operation.  
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In summary our studies demonstrate that total knee arthroplasty results in activation of 
common markers of inflammation, endothelium and coagulation. These changes may 
explain the increased incidence of venous thrombosis and thrombo-embolism post-
operatively as well as a potential risk of venous thrombo-embolism. 
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Introduction 
    
Total knee arthroplasty is a common elective orthopaedic procedure performed in the 
United Kingdom. The number performed has been steadily rising for the last few 
decades with over 12 000 in 2007 (Scottish arthroplasty project). There is a multitude of 
knee prostheses offered by the medical companies but the essential principles of total 
knee arthroplasty remains the same.  
 
The majority of procedures are performed with a tourniquet to minimise intra-operative 
bleeding and to aid the surgeon. A standard midline incision is used with the medial 
parapatellar approach to gain access to the knee joint itself and a degree of soft tissue 
balancing is carried out before a sequence of jigs are used to make the bone cuts on the 
tibia and femur. This then allows the knee prosthesis to be implanted with or without 
polymethylmethacrylate (PMMA) cement, which acts not as the as the name suggests 
but rather as a space filling device much akin to that of grout. 
 
The surgery itself by its very nature causes a degree of soft tissue and bony trauma 
which induces hormonal and metabolic changes. This forms part of a wider systemic 
response to surgical trauma which includes endocrinological, immunological and 
haematological events (Table 1.1). 
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Table 1.1: Systemic response to surgery 
 
 Sympathetic Nervous System Activation 
 Endocrine ‘stress response’ 
      pituitary hormone secretion 
      insulin resistance 
 Immunological & Haematological Response 
      cytokine production 
      acute phase reaction 
      neutrophil leucocytosis 
      lymphocyte proliferation 
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This thesis assesses the effect of uncemented total knee arthroplasty on the activation 
of the immune system and on markers of inflammation. I will also assess any additional 
response evoked from the added use of polymethylmethacrylate (PMMA) bone cement. 
My third study will look at the use of local anaesthetic infiltration intra-operatively in 
uncemented total knee arthroplasty, comparing the effects that this has on the markers 
of inflammation, endothelium and coagulation. My final study will look at the effect of 
the use of drains post-operatively on these markers. The quantification of the 
inflammatory response following elective orthopaedic surgery is important in the light 
of emerging evidence supporting its association between both venous and arterial 
thrombosis as well that of atherosclerosis.  
 
In this introduction I will review the systemic response to surgery, then the immune and 
endothelial response to surgery. I will then summarise the existing literature on these 
responses to total knee arthroplasty, and the effects of bone cement, local anaesthetic 
infiltration and the use of post-operative drains. 
 
 
1.1 The Systemic Response to Surgery 
 
The systemic response to surgery was first described by Cuthbertson in Glasgow Royal 
Infirmary, in 1932 (1) who described in detail the time course of the metabolic 
responses of lower limb injuries in four patients as well as quantifying the magnitude of 
the response. It was here the terms ‘ebb’ and ‘flow’ were first used to portray the time 
course of events which was one of an initial decrease in activity followed by an increase 
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in metabolic activity. The initial work on the ebb phase was partly carried out on 
animals and the flow phase was exaggerated, this has since been redefined (2). 
Following surgical trauma there is the characteristic stress response consisting of the 
hypothalamic activation of the sympathetic nervous system as well as an increased 
secretion of pituitary hormones as well as secretion from the pancreas and thyroid. The 
overall effect of these hormonal changes is to mobilise the energy resources to provide 
energy through catabolism and maintain the intravascular fluid volume through salt and 
water retention. Stimulation of the autonomic sympathetic nervous system also causes 
an increased secretion from the adrenal medulla of catecholamines and norepinephrine. 
This produces the well known ‘fight or flight’ response with tachycardia and 
hypertension.  
 
 
1.1.1 Pituitary hormone secretion 
 
In response to the appropriate stimuli the pituitary gland secretes specific hormones 
either from its anterior or posterior part. The anterior pituitary stimulated by 
hypothalamic releasing factors synthesises adrenocorticotrophic hormone (ACTH), also 
known as corticotrophin. ACTH itself is not secreted but the larger precursor molecule 
pro-opiomelanocortin is initially secreted instead. This is then metabolised into ACTH, 
beta-endorphin (an opioid peptide of 31 amino acids, its circulatory level merely 
reflects the increased secretion from the pituitary gland as itself has no major 
metabolic activity ) and an N-terminal precursor. Adrenocorticotrophic hormone is a 39 
amino acid peptide which stimulates adrenal cortical secretion of glucocorticoids. 
Levels of both ACTH and cortisol rise within minutes of surgery.  
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The cortisol levels reach a maximum at around 4-6 hours later and may increase above 
1500 nmol-1 from a baseline value of around 400 nmol-1 depending on the degree of 
surgery or trauma (3). The usual feedback mechanisms whereby the cortisol 
concentrations have a negative impact on the ACTH secretion are ineffective following 
surgery. Therefore levels of both the cortisol and ACTH remain high during this period. 
Cortisol has a variety of metabolic effects mainly by promoting the breakdown of 
protein and gluconeogenesis in the liver. It also promotes lipolysis producing 
gluconeogenic precursors from breaking down triglycerides to glycerol and fatty acids. 
The glucose produced results in elevated blood levels, the use of glucose by cells is also 
inhibited. As well as this, cortisol has anti-inflammatory activity. It inhibits macrophage 
and neutrophil buildup in areas of inflammation and interferes with the synthesis of 
inflammatory mediators namely prostaglandins. 
 
Other hormones secreted are growth hormone and prolactin. Growth hormone, which 
also goes by the name of somatotrophin, consists of 191 amino acids, it is released in 
response to growth hormone releasing factor from the hypothalamus. The majority of 
its actions are mediated through insulin-like growth factors (IGFs), mainly IGF-1, which 
are small protein hormomes released from liver, muscle and other tissues. As well as 
regulating growth it also has other effects. It produces a positive protein balance by 
preventing protein breakdown at the same time as stimulating protein synthesis. As well 
as this it causes lipolysis (triglycerides into fatty acids and glycerol) and  has an anti-
insulin effect. Its secretion is related to the severity of the trauma or surgery. The 
hormone prolactin has 199 amino acids with a chemical structure not too dissimilar from 
that of the growth hormone. Although released in response to surgery or trauma, and in 
exercise, it does not affect the metabolic activity. 
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The levels of the other hormones secreted from the anterior pituitary such as follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) are not significantly altered by 
surgery.  
 
Arginine vasopressin, a potent antidiuretic hormone (ADH) is released from the posterior 
pituitary. ADH also acts along with corticotrophin-releasing factor and causes the 
release of pro-opiomelanocortin. 
 
 
1.1.2 Pancreatic hormone secretion 
 
Insulin is a polypeptide of two chains of 21 and 30 amino acids, bound together by two 
disulphide bridges. It is the main anabolic hormone (3). After food intake it is released 
from the pancreas specifically from the beta cells. It promoted the uptake of glucose 
into muscle to form glycogen and into fat cells for conversion into triglycerides. The 
conversion of glucose to glycogen in the liver is also in response to insulin. As well as its 
anabolic effects it inhibits catabolic events such as protein catabolism and lipolysis. 
However there appears to be a failure of insulin secretion that one would expect to 
accompany the catabolic, hyperglycaemic response seen intra-operatively. This may in 
part be due to the α-adrenergic inhibition of β cell secretion. As well as this there is 
also the lack of the ‘insulin resistance’ response in the perioperative period. 
 
The pancreas is also responsible for the secretion of glucagon from α cells. Its main 
effects are in the promotion of hepatic glycogenolysis and in increasing glucose 
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production in the liver from amino acids. It also promotes lipolysis. However after major 
surgery despite a rise in the concentrations of glucagon it does not significantly add to 
the increased glucose levels see in the stress reponse. 
 
 
1.1.3 Thyroid hormone secretion 
 
Thyroid stimulating hormone (TSH) results in the secretion of thyroxine (T4) and tri-
iodothyronine (T3) as well as  small amounts of the inactive reverse T3 (r T3). T3  is 
produced peripherally in the tissue where the T4 undergoes mondeiodination. 
Metabolically T3 is in the order of three to five times more active than that of T4. A 
siginifcant proportion of these hormones are protein bound, mainly to thyroid-binding 
globulins (TBG) and thyroxine binding pre-albumins. It is the free unbound percentage 
that is metabolically active but these low concentrations remain in balance with the 
concentrations bound to protein in tissue and plasma (4).  
 
The thyroid hormone activity affects both metabolism and heat production. It also 
stimulates the central and peripheral nervous systems and causes an increased amunt of 
carbohydrate absorption from the gastro-intestinal tract. The activity of the thyroid 
hormones is closely linked to catecholamines in that it increases the affinity as well as 
the number of the β-adrenoceptors in the cardiac muscle and thereby increasing its 
response to the catecholamines. Following surgery the TSH levels decrease in the first 
few hours post-operatively but soon return to their pre-operative levels. The cause of 
which, is yet unknown.         
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The net effect of this following surgery is to provide energy from the breakdown of 
resources such as from carbohydrate, protein and fat. Soon after surgery starts the 
blood glucose concentrations increase from increased liver glycogenolysis and 
gluconeogenesis in response to cortisol and catecholamine levels. The uptake of glucose 
peripherally is reduced. The level in the blood is proportional to the degree of the 
surgical insult closely following the rise in catecholamines. Due to the apparent lack of 
glucose control during this period there is a period of hyperglycaemia due to the 
increased production of glucose, the reduced levels of insulin and the insulin resistance 
peripherally. The protein catabolism that occurs mainly involves skeletal muscle but 
visceral muscle is also broken down to its amino acids. These may then be further used 
to provide energy or alternatively be used to form acute-phase proteins in the liver. 
With regard to fat the net result is that of increased mobilisation of triglycerides 
however this does not appear to significantly affect the concentrations of fatty acids 
and glycerol in the plasma. 
 
The intravascular volume is maintained by the release of arginine vasopressin which 
causes the retention of water. This increased secretion may continue for several days 
following surgical trauma. The kidneys release rennin which in turn causes the release 
of angiotensin II which stimulates the release from the adrenal cortex of aldosterone. 
The aldosterone then stimulates the distal convoluted tubules of the kidney to absorb 
both sodium and water (5). 
 
The endocrine response to surgical trauma is first activated by impulses travelling along 
sensory nerve roots to the spinal cord and medulla with activation of the hypothalamus. 
It was hypothesised in the 1950s that certain ‘wound hormones’ may be present at the 
site of the injury which may be in part be responsible for this response. In the now 
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classical studies by Egdahl (6) it was proved from measuring the adreno-coritcal 
response in canine lower limb trauma in those with either an intact sciatic nerve, or one 
that was transected, that there was no elevated levels  adrenal hormone in those with a 
transected sciatic nerve. However this general idea that the presence of these ‘local 
substances’ may contribute to the wider stress response seem following surgical trauma 
was again brought to the forefront with the evolving research into cytokines. 
 
 
1.2 Cytokines 
 
From 1950 to 1970 the early studies on cytokines described a number of protein factors 
which were shown to mediate certain functions and were produced by different cell 
types. They were termed lymphokines as evidence at that time pointed to the T 
lymphocytes from the thymus as the cells involved in the secretion of these protein 
factors. As cytokine research evolved many individual cytokines were identified. It came 
to light that cytokines were synthesised mainly from leucocytes and it was shown that 
the majority of its actions were directed to other leucocytes, it was at this time they 
were renamed as interleukins. Often the same cytokine mediated a diverse array of 
effects. The exact identification and distinction between the various cytokines was due 
to impure preparations and non specific antibodies for the cytokines. But over the past 
decade with the use of molecular cloning and the availability of more specific 
antibodies, the properties and structure of these cytokines has been made possible.  
 
In the presence of tissue trauma these low molecular weight proteins (<80 kDa) can be 
released from leucocytes (particularly monocytes), endothelial cell as well as 
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fibroblasts. Following binding to a specific cell receptor they can alter the cellular RNA 
and affect protein synthesis and it is through this process that they are able to change 
and regulate cell growth as well as cell development and repair. They alter the cell 
behaviour through signaling pathways which are predominately intracellular to affect 
gene transcription (7). Unlike hormones which are secreted into the circulation and 
affect target cells some distance away cytokines are released to act on either nearby 
cells (paracrine) or on the same cell (autocrine). They have been termed pleiotropic as 
they act on many different cell types and usually have more than one effect on the 
same cell as well as influencing the synthesis and action of other cytokines. They also 
have a significant role to play in inflammation and immunity and are very powerful at 
very low concentrations (8). They are extremely potent and generally act at picomolar 
concentrations. The effect that a specific cytokine will have on a cell will depend on a 
number of variables such as the levels of the cytokine  as well as other regulators which 
may be present (5).  
 
The majority of cytokines are synthesised and secreted when needed with exceptions 
such as transforming growth factor-beta (TGF-β) stored in platelet alpha granules (9) 
and tumour necrosis factor-α (TNF-α) in mast cells (10). Once synthesized cytokines 
such as TNF-α and interleukin 1β (IL-1β) are stored as membrane proteins (11). They 
may also bind to an extracellular matrix or a cell surface protein to form a complex 
such as with interleukin-8 (IL-8) (12;13).   
 
Cytokines have a local and systemic role in response to surgical trauma. The main 
cytokines involved are interleukin-1 (IL-1), tumour necrosis factor α (TNF-α) and IL-6. 
Following surgical trauma it is the IL-1 and TNF-α which is released first from the 
macrophages and monocytes locally, followed by IL-6 and other cytokines are released 
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(figure 1). But it is the IL-6 that is mainly responsible for inducing the acute phase 
response (5). 
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Figure 1: Cytokine cascade – Inflammatory cytokines are released from activated 
immune cells in the plaque i.e. interferon γ, interleukin-1 and tumour necrosis factor 
which induces the production of IL-6. IL-6 in turn stimulates the production of acute-
phase reactants such as C-reactive protein, serum amyloid A and fibrinogen. (Image 
taken from Hansson, NEJM 2005 (14), reproduced with kind permission of NEJM) 
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1.2.1. Cytokine Receptors 
 
The current knowledge on cytokine receptors is that they are transmembrane proteins. 
The cytokine binds to the extracellular domain and the intracellular domain can have an 
enzymatic activity, bind with other molecules or use a second messenger system. There 
are also proteins that exist which are structurally similar to cytokine receptors which 
are not membrane bound.There are seven families of cytokine receptors grouped either 
according to the structure of the cytokineor intracellular receptor, or by the type of 
signal messaging. But the majority of cytokines have different components of their 
extracellular cytokine receptors which can belong to more than one of the family of 
receptors. 
 
- Group1 
This group usually has more than one extracellular immunoglobulin domain. Although it 
mainly involves the receptors for IL-1α and β there are also sequences for IL-6R, M-CSF 
and PDGF. The IL-1α has a higher affinity for the type I receptor with the IL-1β binding 
more to the type II receptor (15).  There is also a soluble IL-1 present and there is 
evidence suggesting that the type II receptor may play a role in binding with this soluble 
form and in a way affect the IL-1 activity (16). To support this, there is an IL-1 binding 
protein which matches the type II receptor binding site (17). 
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- Group 2 
This group formerly known as the haematopoietic receptor family is the biggest group. 
These bind to cytokines with a four α-helical strand structure such as IL-2 to IL-7, G-CSF 
and GM-CSF. 
 
- Group 3 
These are the type I interferon receptors which binds to IFN-α and IFN-β and the type II 
receptor binds to IFN-γ. 
 
- Group 4 
These are the nerve growth factor receptors which include the two TNF receptors for 
TNF-α and β. Either receptor has equal affinity for both TNF-α and β (18) but they 
appear to transmit different signals as the intracellular components differ.  
 
Also present are two soluble TNF binding proteins which are present in the healthly 
population not only in the serum but also in the urine. Although the concentrations 
normally around 1-2 ng ml -1 have been shown to vary from individual to individual they 
seem to be stable in individuals over time (19). Increased concentrations exist in various 
conditions like endotoxinaemia (20), systemic lupus erythematous (21), and in 
malignancies and infections (22;23). 
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1.2.2 Cytokine Signal Pathways 
 
These pathways are inititated when the cytokine binds to its receptor. The most 
common pathway involves protein phosphorylation. Some receptors will have intra-
cellular enzyme messenging  through tyrosine kinase activity), whereas other will use G 
(GTP-binding) proteins.  
 
The initial cytokine signal can be further amplified by second messenger systems such as 
by cyclic-AMP-phosphokinase A,  regulated by phosphokinase C (24). Phospholipase 
make up the other second messengers. Phospholipase C produces inositol triphosphate 
(IP3) and diacylglycerol (DAG) which help regulate calcium within cells (25) and in 
activating protein kinase C (26). 
 
Following stimulation by the cytokines there can be a rapid or delayed response over 
hours or days. Ultimately resulting in altering protein synthesis through gene 
transcription.  
 
Signal transduction and gene transcription is currently being further researched as it 
presents the possibility of intervention and modulation. 
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1.2.3 Tumour necrosis factor 
 
Tumour necrosis factor alpha (TNFα) is produced as a pro-hormone, this is then cleaved 
to give a 157 amino acid  (27). Interaction with a specific receptor results in its 
biological response It is extremely potent requiring only 5% of its receptors to be 
occupied in order to produce a biochemical response (28). Tumour necrosis factor 
consists of two different polypeptides, TNF-α and TNF-β are different antigenically. It 
has a key role along with IL-1 in the initiation of inflammation and the immune 
response. But over production of TNF is potentially lethal to the host as seen in 
cachexia (29), autoimmune disorders (30) and meningococcal septicaemia (31). The TNF 
proteins are involved in a multitude of processes through its ability initiate many 
different signal transduction paths as well coding for cytokines and acute phase proteins 
(32).  
 
As with the TNF there are also two TNF receptors, TNFR-I and TNFR-II. Either receptor 
shows the samw affinity for binding on to either TNF-α or TNF-β. Also present in the 
serum, are soluble TNF binding proteins acting as receptors which compete with the 
bound receptors (33).  
 
Tumour necrosis factor is chemotactic for polymorphonuclear leucocytes (PMNL) and 
causes these cells to release oxygen-derived free radicals. 
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1.2.4 Interleukin-1  
 
When activated either endothelial cells or macrophages can release interleukin-1 which 
has a short half-life of around 6 minutes. Similar to TNF IL-1 can be present in two 
forms, IL-1α and IL-1β. Both with an equal affinity for their receptors. IL-1α produces its 
signal through cellular contact. In comparison IL-1β is present in the circulation and 
produces similar physiological and metabolic effects to that of TNFα (15). Compared to 
TNF it has more inflammatory and immunoenhancing effects. It can stimulate 
myelopoesis directly or indirectly through myelopoetic growth factors such as GM-CSF. 
It is an endogenous pyrogen and is involved in the anorexic process (34).  
 
As with TNF the main stimulus for its release is lipopolysaccharide (LPS) endotoxin 
antigen. Both TNF and IL-1 seem to enhance each other’s effects when present together 
(34). Together they cause the release of prostaglandins and IL-6 from monocytes and 
endothelial cells. It also causes the release of tissue factor from monocytes and 
endothelium as well as down-regulating the expression of thrombomodulin and so the 
inflammatory process shifts the haemostatic balance from anticoagulation to 
coagulation (35). But unlike TNF it does not stimulates the degranulation of PMNLs to 
release oxygen free radicals. 
 
In general IL-1α and IL-1β binds to IL-1R type I and IL-1R type II respectively. Recent 
evidence shows that all the effect of IL-1 is due to the transducing signal from IL-R type 
I receptor. The function of IL-1R type remains unknown, but similar to TNF it may act to 
antagonise and regulate the activity of IL-1 (16;36).  
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1.2.5 Interleukin-6 
 
The acute phase response involves TNF, IL-1 and IL-6 is a mediator of the acute phase. 
The chances of a subsequent MI following a previous episode increases with increasing 
baseline IL-6 concentrations (37). Interleukin-6 works by binding to a receptor complex 
which is made up of IL-6R (80 kDA protein) and gp-130 (130 kDA signal transducing 
glycoprotein) (38). Interleukin-6 binds to the receptor IL-6R with only low affinity but 
binds with high affinity in the presence of gp-130. Without IL-6R, IL-6 will not bind to 
gp-130 unless soluble IL-6 receptor (sIL-6R) is present. This is in contrast to the situation 
with TNF where the binding of TNF to soluble TNFR renders TNF inactive. The 
significance and regulation of soluble IL-6R is currently poorly understood but what is 
known is that increased serum concentration is seen in certain pathological conditions 
such as multiple myeloma, HIV infection and adult T cell leukaemia. The soluble IL-6 
will enhance the actions of IL-6 (39) possibly due to soluble IL-6 binding with IL-6 and gp 
130 without the need for a cytoplasmic region (40). This in contrast to most other 
receptors which require their own cytoplasmic regions for signals.  
 
As well as its inflammatory role it also has a role to play in host defence, immune 
response and haematopoiesis. Chronic activation is seen in rheumatoid arthritis. 
 
Following surgical trauma IL-6 levels begin to rise and reach significant levels at around 
2-4 hours. The cytokine production levels reflect the degree of surgical trauma and so 
the largest responses are seen in joint replacement surgery, colorectal and major 
vascular surgery (41). In terms of total knee arthroplasty bilateral simultaneous 
replacements exhibit a significantly larger IL6 response (42). The levels will reach their 
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maximal point at around 24 hours, remaining elevated for up to 48 – 72 hours (43), so 
therefore secretion is a brief and self-limiting event. 
 
There may be some variability between individuals in their response to an inflammatory 
stimulus, as the increases in IL-6 and CRP seen in those following coronary angioplasty 
or uncomplicated cardiac catheterisation correlate linearly with baseline and CRP and 
IL-6 levels (44). This variability in the degree of response may also have a genetic basis 
(45). In terms of the response to surgical trauma there has been some correlation found 
between the duration of surgery and the magnitude of the IL-6 response (41). 
 
Current evidence now suggests that elevated IL-6 and CRP levels carry not only  more 
risk of  subsequent development of atherosclerosis but also the risk of developing type II 
diabetes, even in those with no current evidence of insulin resistance (46). 
 
 
1.2.6 Interferon-γ 
 
Interferon-γ (IFN-γ) is produced from human T helper lymphocytes as well as from 
natural killer (NK) cells. It levels become detectable at around six hours and remain so 
for eight days. Tissues which have undergone surgical trauma such as operative wounds 
also result in IFN- γ production up to 5 to 7 day afterwards (47).   
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1.2.7 Macrophage / Granulocyte Colony Stimulating Factor 
 
M/G CSF is involved in stimulating leucocytes in the inflammatory response and can also 
be effective in the wound healing process. Patients undergoing oncologic procedures 
who have been given macrophage colony stimulating factor (M-CSF) peri-operatively and 
in those with major burns have shown increased neutrophil activity. 
 
 
1.3 Acute Phase Response 
 
Following surgical trauma there is an ‘acute phase response’ which results in the 
release of certain cytokines. As part of this response the liver produces and releases 
acute phase proteins (Table 3) which have a role in the mediation of the inflammatory 
response and in tissue repair. The increased levels of C-reactive protein (CRP) follows 
that of IL-6. C reactive protein allows for the phagocytosis of bacteria, alpha2 
macroglobulin and anti-proteinases. There are many proteins involved. Some are useful 
markers of the size of an inflammatory process. 
 
Following surgical trauma the release of cytokines (proportional to the degree of 
surgical trauma) may further increase the release of ACTH from the pituitary and so 
further increase the cortisol levels. This does not occur as the initial release of cortisol 
following surgical trauma is enough to depress the IL-6 levles (8).  
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As the response seen in the cytokines is in direct relation to the severity of the local 
tissue trauma the type of anaesthetic will have no effect on this response. However, the 
use of regional anaesthesia can reduce the response to surgery. As seen in pelvic and 
lower limb surgery, an epidural block along with local anaesthetics will stop the 
metabolic and endocrine response usually seen following surgery. It has been 
demonstrated that a T4 to S5 blockade will prevent the increase in cortisol and 
therefore the increase in glucose following hysterectomies (48). 
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Table 1.2: Features of the acute phase response  
 
Features of the acute phase response 
Fever 
Granulocytosis 
Production of acute phase proteins in liver 
   CRP 
   Fibrinogen 
   α2-macroglobulin 
Concentration changes in transport proteins 
   Increased ceruloplasmin 
   Decreased transferring, albumin and α2-macroglobulin  
Concentration changes of divalent cations 
   Copper increases 
   Zinc and iron decreases 
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This is due to the blocking of the signals from the site of trauma to the central nervous 
system as well as to the hypothalamus as well as the efferent signals to the liver and 
adrenal medulla. Therefore abolishing the signals to the adrenocortex and the 
glycaemic responses to surgery. But in the presence of a less extensive blockade this 
will not occur. A recent animal study has shown that even the use of local lignocaine 
can attenuate the local acute phase response (49) 
 
In cases of severe polytrauma a more severe response may occur. This systemic 
inflammatory response syndrome was defined by the American College of Chest 
Physicians/Society of Critical Care Medicine (ACCP/SCCM) as the ‘Systemic Inflammatory 
Response Syndrome’ (SIRS) in 1991 (50). For the diagnosis of SIRS to be made it was 
agreed that at least two out of the four clinical markers must be present (Table 1.3). 
 
In orthopaedic surgery the surgical stress response to an orthopaedic procedure has 
been sub-divided into either a primary or a secondary stress response (51). The primary 
stress response is that which is seen following any elective orthopaedic operation. On 
the other hand if the patient has already undergone a traumatic event such as a hip 
fracture following a fall then an emergency operation to deal with the hip fracture 
would induce a secondary stress response. 
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Table 1.3: Clinical parameters in SIRS 
 
Clinical Parameters Values 
Heart rate >90 / min 
Breathing rate >20 / min 
Temperature >38oC or <36oC 
Number of leucocytes >12,000 / mm3 or <4000 / mm3  
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This has been termed the ‘second hit phenomenon’ (52), the ‘first hit phenomenon’ 
(53;54) being the initial response induced from the hip fracture. The second hit 
phenomenon has been demonstrated in a paper by Giannoudis et al which reported 
significant increases in the IL-6 and elastase levels following intramedullary nailing of 
femoral fractures (55). As mentioned previously the degree of surgical trauma is related 
to the size of the stress response, but there has also been evidence to suggest that 
there are potential gender differences in the response as reported by Ono et al. (56) 
who reported higher levels of TNF-α and suppressive interferon production in men 
following gastrointestinal surgery. It was concluded that men were at a higher risk of 
developing SIRS and post-operative infectious complications. These gender variations in 
stress response have also been supported by other authors (57;58). 
 
The inflammatory mediators have an important role to play in the acute phase response 
but research over the last few decades has shown a role that inflammation plays in the 
initial formation and progression of atherosclerosis and in venous thromboembolism. 
 
 
1.4 Circulating markers of Atherosclerosis, Thrombosis and Inflammation 
 
In the 1970’s atherosclerosis was seen as a lipid storage disease with the lipid deposited 
in the arteries which eventually builds up eventually causing a blockage of the artery 
resulting in a myocardial infarction (MI) or a stroke. But recent research has shone some 
light on the process and development of atherosclerosis. Inflammation appears to be 
key here and the development of these plaques occur within and not on the arterial 
walls as previously thought. 
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Atherosclerosis has been shown to develop slowly over decades starting as the ‘initial 
fatty streak’ and slowly becoming the complex plaques causing potentially 
cardiovascular events. 
 
The innermost surfaces of arterial walls are lined by endothelial cells (EC), normally 
these will resist the adhesion of leucocytes. But this all changes when the endothelial 
cells express adhesion molecules in response to certain factors such as high saturated 
fat diet, smoking, high blood pressure, hyperglycaemia and insulin resistnace or obesity. 
The vascular cell adhesion molecule-1 (VCAM-1) is an example of an adhesion molecule 
which allows the adhesion of both monocytes and T-lymphocytes, both of which are 
present in the early developping plaque (Figure 1.2).  
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Figure 1.2: Role of T-lymphocytes in atherogenesis (from Libby, Inflammation in 
atherosclerosis, Nature 2002 (70) , produced with kind permission from Nature) 
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Under normal conditions the central lipid core of these plaques are protected from the 
bloo contact by a fibrous cap but when this cap fractures it causes the majority of the 
acute coronary syndromes. This usually results in the formation of a thrombus which will 
cause an increase in the size of the plaque. The biomechanical strength and resilience 
of the cap is due to the interstitial collagen and what has been shown is that in those 
plaques that have ruptured the collagen cap has been thinner than expected (59-61). 
The smooth muscle cells of the arterial wall produce collagen in response to stimulatory 
factors such as IL-1, platelet-derived growth factor and transforming growth factor-β . 
But the T lymphocytes which are present in the plaque has been shown to produce 
interferon-y which not only inhibits the basal collagen formation but also the inhibits 
the stimulatory effect on the smooth muscle cells to produce collagen (62). As well as 
this CD40 ligand and IL-1 is also released from the T-lymphocytes causing the release of 
enzymes responsible for collagen degradation (63). 
 
 
1.4.1 Vascular Cell Adhesion Molecule-1 and MCP-1 
 
Mice studies have shown that there is a reduction of lesion formation in those with a 
poorly functioning VCAM-1 compared with normal VCAM-1 expression (64). The 
expression of VCAM-1 is in response to the presence of oxidized lipids mediated by 
cytokines such as nuclear factor-kβ, interleukin-1β and tumour necrosis factor-α.  
 
Laminar blood offers protection against the lesion formation due to the shear stresses 
generated which causes the release of nitric oxide which reduces the expression of 
VCAM-1 through the inhibition of nuclear factor-α and platelet clumping (65) (66). 
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Therfore areas which lack this laminar blood flow are susceptible to lesion formation. 
This has been supported by studies which showed that endothelial cells which lack this 
laminar blood flow have increased expression of nuclear factor-κβ (67). 
 
Once adhered, the monocytes enter between the endothelial cells through diapedesis 
(figure 1.3). The main chemotaxis for this comes from the monocyte chemotactic 
protein-1 (MCP-1). Without the expression of MCP-1 there is up to 83% less lipid deposit 
in the vasculature of mice and less leson development compared to MCP-1 producing 
mice on the same high fat diet (68) (69). Once within intima, macrophages are formed 
from matured monocytes. These macropages engulf the lipoproteins and become foam 
cells and as there numbers increase they release further cytokines and growth factors 
perpetuating the cycle. The macrophage colony-stimulating factor (M-CSF) is the main 
mediator of this process confirmed by its over expression in experimental and human 
atherosclerotic plaques (70). Although other cytokines and growth factors are involved 
in the initiation of this atherosclerotic lesion it is the VCAM-1, MCP-1 and M-CSF that are 
the key mediators (figure 1.3).  
 
 
1.4.2 CD40 ligand (CD154) 
 
CD40 ligand (CD154) is another proinflammatory cytokine which contributes to 
atherogenesis, expressed by leucocytic as well as non-leucocytic cells such as platelets. 
CD154 is stored pre-synthesised in platelets and released in vitro in seconds after 
activation and in the formation of thrombus (71). CD154 interacts with CD40. 
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Interrupting the CD154 signalling pathway will slow the initiation of atherosclerosis (72). 
Following this further research was carried out to see if interruption of this pathway 
affected the atherosclerotic progression after the lesion had already been established. 
It seems that in preventing CD154 signalling the formation as well as the evolution of 
established plaques is prevented (73). 
 
Also a recent study by Ray et al (74) pointed towards an association of CD40 ligand and 
the thrombotic cascade but did go as far as to state there was a relationship indicating 
possible further studies to investigate this. 
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Figure 1.3: Steps in the recruitment of mononuclear phagocytes to the nascent 
atherosclerotic plaque and some of the functions of these cells in the mature 
atheroma (from Libby Nature 2002 (75), produced with kind permission from Nature). 
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1.4.3 Soluble CD40 Ligand 
 
In contrast to the membrane bound CD40L, soluble CD40L (sCD40L) is released mainly 
from platelets (76). The levels of sCD40L correlate with platelet activation and can 
identify those at risk of having recurrent ischaemic event (77;78) in patients with known 
ischaemic heart disease but is not a useful tool in low risk subjects. (79) 
 
The current value of sCD40L as a marker is unknown and further research is needed to 
evaluate whether sCD40L is of value in the prediction of future cardiac events in a 
healthy population. It may be more useful as an indication of plaque stability and some 
pilot studies have shown that sCD40L is more closely associated with plaque composition 
than volume (80). 
 
There is conflicting evidence as to whether soluble CD40 ligand correlates to CD40L with 
some suggesting a positive correlation (81) and others a negative (82). Varo et al. (83) 
highlighted variables that may significantly affect this correlation, these included the 
time between collection and analysis, centrifugation and the storage temperatures. He 
stated that this could be avoided through a standardised approach. 
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1.4.4 CD40 
 
CD40 regulates a wide variety of biological functions, extending from cellular immunity 
to inflammation, two processes intimately involved in atherogenesis. As such, the 
endothelium in vessels within inflamed tissue show an increased CD40 expression (84). 
CD40 signalling can promote the expression of proatherogenic mediators such as certain 
MMPs, caspase-1, and procoagulant activity. 
 
 
1.4.5 CD14 
 
In the First Leukocyte Typing Conference held in 1982 a set of monoclonal antinbodies 
were identified and collectively named unde the title of CD14. These bound only to 
monocytes and macrophages and so could be used to highlight cells which were of 
monocytes or macrophage lineage. 
 
CD14 is a 55kDa membrane glycoprotein, consisting of 356 amino acids and a 19 amino 
acid long N-terminal leader peptide. It is as a receptor for the endotoxin 
lipopolysaccharide (LPS) (85) which is found in gram-negative bacteria with only small 
amounts resulting in a rapid immune response. LPS in plasma is bound to LPS binding 
protein (LBP) which mediates the binding of CD14 to LPS. This results in the production 
of inflammatory cytokines such as TGFβ. CD14 also interacts with other bacteria and 
fungi, demonstrating its role in innate immunity (86). 
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The synthesis and expression of CD14 in monocytes has several mediators such as IL-4 
and IL-3 which will reduce the expression of CD14 at the transcriptional level in 24-
48hrs (87-89) whereas IFNα, IFNγ and TGFβ (90) increases CD14 expression. 
 
Recent in vitro experiments suggests that CD14 has other biological functions such as its 
monocyte-endothelial cell interactions (91). The more mature subpopulation of 
monocytes, the CD14+/CD16+, have increased numbers in infectious diseases such as 
sepsis, tuberculosis, the critically ill and in uraemic patients without infections (92-94). 
It has also been suggested that they have a role in the induction of the inflammatory 
process involved in atherosclerosis (95). Increased levels are also seen in patients with 
with coronary artery disease (96). Schlitt et al demonstrated in their study that patients 
with the highest percentages (upper quartile) of CD14+/CD16+ monocytes had an odds 
ratio of 4.7 for coronary artery disease after confounding factors such as diabetes, 
hypertension and lipid profile were considered. Highlighting it as an independent risk 
factor for coronary artery disease.    
 
 
1.4.6 CD42a 
 
CD42a belongs to the mucin family and is a small membrane glycoprotein found on the 
surface of platelets. It combines with CD42b, CD42c and CD42d to form the CD42 
complex which acts as a receptor for von Willebrand factor and as a vWF-dependant 
adhesion receptor and so mediates the adhesion of platelets at high shear rates to vWF 
in the subendothelial matrices which are exposed when the endothelium is damaged. It 
also amplifies the response of platelets to thrombin during platelet activation. 
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1.4.7 CD14/CD42a dyad (platelet-monocyte aggregate) 
 
Current evidence suggests that patients who have undergone an acute coronary 
syndrome have both increased interactions between platelets as well between platelets 
and leucocytes, with the later forming in inflammatory states (97).  Platelets adhere to 
circulating leucocytes following activation and degranulation. The P-selectin on the 
surface of the platelets binds to the P-selectin glycoprotein ligand-1 (PSGL-1) on 
leucocytes (98). This in turn causes a further expression of CD11b/CD18 on leucocytes 
enhancing the interaction with platelets (99). A recent study has supported the 
importance of platelet-leucocyte interaction in vascular disease were human PSGL-1 
reduced the degree of reperfusion myocardial damage and endothelial dysfunction in an 
animal model (100). 
 
There is growing evidence demonstrating the importance of platelet-leucocyte 
aggregation in atherothrombosis and acute coronary syndromes. Sarma et al (101) 
demonstrated that higher levels of platelet-monocyte were found those with an acute 
coronary syndrome and that this was drastically reduced when the PSGL-1 and P-
selectin receptors were blocked. Therefore adding further evidence that platelet 
monocyte binding occurred through PSGL-1 and P-selectin (101). This has been 
supported by other studies (102). The exact role of platelet-monocyte aggregates in 
acute coronary syndrome is unknown, whether they are a reflection of the inflammatory 
and thrombotic process or a directly contribute to the ongoing atherothrombogenesis. 
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1.4.8 C-reactive protein 
 
Out of the acute phase proteins C-reactive protein was the first one described and is 
very sensitive in reflecting the ongoing inflammation and tissue damage (103). Plasma 
CRP is released from liver hepatocytes in response to IL-6produced predominantly from 
hepatocytes mainly under transcriptional control by IL-6. The CRP levels show no diurnal 
variation and are unaffected by eating.  
 
The median concentration of  CRP in young healthy adults is 0.8 mg/l ranging from 3.0 
mg/l (90th centile) to 10 mg/l (99th centile) (104).  However, following an acute stimulus 
the concentration levels may increase by 10,000 fold. Following stimulation CRP 
synthesis and secretion starts rapidly with levels reaching greater than 5 mg/l by 6 
hours and eventually peaking at 48 hours. It’s half-life (around 19 hours) remains 
constant under all conditions and so its rate of synthesis will determine its circulating 
concentration (105) and is a direct measure of the intensity of the pathological 
stimulus. When the stimulus is removed the levels of CRP fall almost at the rate of 
plasma CRP clearance. 
 
C-reactive protein belongs to the pentraxin family of calcium-dependant ligand-binding 
plasma proteins along with serum amyloid P component (SAP). The pentraxin family was 
named as such due to it electron micrographic appearance from the Greek penta ragos  
(five berries). It is made up of 5 identical nonglycosylated polypeptide subunits, each 
subunit with 206 amino acids arranged in a cylic pentameric symmetry (figure 1.4) 
(106).  
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C-reactive protein (CRP) has been shown to have a strong association with with the risk 
cardiovascular disease in healthy people. Although the main source is from the liver, 
complements proteins and arteries can produce CRP. The presence of C-reactive protein 
on its own may stimulate the releas of IL-1β, IL-6 and TNF-α from monocytes (107) and 
causes the expression of ICAM-1 and VCAM-1. Ridker et al in their study demonstrated a 
lower risk of recurrent myocardial infarction (MI) and death from cardiovascular cause 
in those on statin therapy with a lower CRP (less than 2mg/L) (108). High-sensitivity 
assays have allowed studies to demonstrate a relationship between increased CRP levels 
and risk of stroke and progression of peripheral arterial disease (109-112). A meta-
analysis of all published studies in 2000, totalling 1,953 coronary events demonstrated 
that those with base values of CRP in the upper third had a relative risk of 2.0 for a 
future coronary event (112). 
 
However a more recent meta-analysis by Danesh et al in 2004 (113) gave a slightly 
different result. This included 22 prospective studies with a total of 7068 patient with a 
weighted mean follow-up 12 years. But they found that studies published before 2000 
tended to have more extreme conclusion and made the decision to limit their analysis 
to four studies with over 500 patients in each (a total of 4107 patients). This gave an 
overall odds ratio of 1.49 (93% CI of 1.37- 1.62) compared to that of 1.58 (95% CI 1.48 – 
1.68) when all 22 studies were included. The authors concluded that the levels of C-
reactive protein was only a moderate predictor of the future risk of coronary heart 
disease in the presence of already well established risk factors. 
 
The Lancet published its results of a meta-analysis from the Emerging Risk Factors 
Collaboration in 2010 with over 160 000 individuals with no past medical history of 
vascular disease (114). They concluded that the CRP concentration had a continuous 
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association with the risk of heart disease, stroke and vascular mortality because it was 
similarly associated with non-vascular mortality but its relevance in pathogenesis was 
unclear. They also noted that the association with ischaemic vascular disease depended 
significantly on the conventional risk factors as well as other markers of inflammation. 
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Figure 1.4: A – Electron micrograph showing pentameric disc-like structure face-on 
and side-on (arrows). B – Ribbon diagram showing the lectin fold and the 2 calcium 
atoms (spheres) in the ligand-binding site of each protomer (from Pepys et al, J Clin 
Invest 2003 (103), reproduced with kind permission from J Clin Invest). 
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1.4.9 Tumour necrosis factor alpha 
    
Tumour necrosis factor alpha (TNFα) is a trimeric protein it was first discovered as a 
17kd secreted form but later a noncleaved 27kd precursor form was found in a 
transmembrane form (115). The 27kd TNFα form is secreted from activated 
macrophages but it can also be produced from other cell types it then binds to tumour 
necrosis factor receptors 55 and 75 through cellular contact or bind following cleavage 
to its soluble form. TNFα has to ability to transform from a hydrophobic to hydrophilic 
form allowing it cross cell membranes as well as forming ion channels. It has been 
speculated that this is due to its structural resemblance to that of viral coat proteins 
(116).  
 
Tumour necrosis factor alpha is a pleiotropic cytokine. It appears to influence the 
majority of the organs in the body and has a wide spectrum of functions many of which 
are not understood. It can both stimulate and inhibit growth as well as self regulatory 
properties. An example of this is that TNFα can cause neutrophil proliferation as well as 
apoptosis during inflammation and binding to the TNF-R55 receptor respectively (117).  
 
It has beneficial functions such as its role in the necrosis of certain tumours as well as 
the role it plays in the immune response to infection from either bacterium, viruses or 
parasitic causes. Tumour necrosis factor has a key role to play in the inflammatory 
response locally as well as being one of the acute phase proteins. Without TNFα, mice i 
with gram negative bacteria undergo septicaemic shock (118).  
 
81 
 
1.4.10 E-selectin 
    
This was originally known as the endothelial leukocyte adhesion molecule (ELAM) 
because of its localisation to the endothelium and its role in binding leucocytes to the 
endothelium.  However when two other similar adhesive glyoproteins were identified, 
(the homing receptor and granule membrane protein of molecular weight 140kD) they 
were renamed under the nomenclature of selectins, with ELAM being renamed as E-
selectin (119), the homing receptor named L selectin and the granule membrane protein 
of molecular weight 140kD was named the P selectin. 
 
All three selectins are either expressed on the surface of platelets (P selectin), vascular 
endothelial cells (E and P selectin) and leucocytes (L selectin) and function in binding to 
ligands to promote intercellular adhesion. E-selectin is thought to be expressed only on 
activated endothelial cells and its expression is induced by cytokines (120).  
 
In addition to mediating leucocyte rolling it is also involved in the conversion from 
rolling to adhesion. This has been shown by a reduction in adherent leucocytes in mice 
that are E-selectin deficient (121) (122). Under baseline conditions, E-selectin is 
expressed by the microvessls of the skin (123) and evidence suggests that it plays an 
important role in skin inflammation through its role in the recruitment of T lymphocytes 
specific to the skin (124). The three-dimensional structure of E-selectin (Figure 1.5) was 
determined using x-ray crystallographic methods (125).  
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1.4.11 Tissue plasminogen activator 
 
In normal healthy endothelium, thrombus formation is inhibited by several mechanisms. 
There are the endothelium-derived inhibitors of coagulation such as thrombomodulin, 
heparin sulphate, protein S, proteoglycans and tissue factor inhibitor, as well as 
prostacyclin and nitric oxide (NO) which prevent the aggregration of platelets. But 
following injury or inflammation there is a downregulation of these mechanisms and 
endothelium becomes procoagulant with tissue factor expression and the realease of 
fibronectin, vWF and platelet activating factor (126). 
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Figure 1.5: 3D image of E-selectin (reproduced with kind permission from the 
University of Virginia Biomedical engineering website). 
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 After thrombus formation has begun tissue plasminogen activator (t-PA) is released 
mainly in response to factor Xa and to thrombin (127). T-PA causes the breakdown of 
the thrombus to soluble fibrin byproducts through converting plasminogen to plasmin 
which is accelerated by the presence of fibrin at the endothelial cell surface, (128;129) 
producing localised activation. It is the t-PA release which determines the onset and 
efficacy of fibrinolysis as plasminogen is present in vast quantities compared to t-PA. 
     
In human plasma the concentration of t-PA is around 3 to 10 ng/ml. But serine protease 
inhibitors (serpins); mainly plasminogen activator inhibitor (PAI) type 1(PAI-1) as well as 
PAI-2, PAI-3, ensure that only a small amount is activeproportion is functionally active 
(130). The half-life of t-PA is around 5 minutes and is cleared by the liver (131).  The 
percentage of active t-PA varies from 2% to 33% (132). 
     
Tissue plasminogen activator is a 68 kDa serine protease consisting of 530 amino acids. 
Endothelial cells in culture synthesise and secrete t-PA (133). The presence of histamine 
and thrombin will stimulate its synthesis (134) whereas plasmin will inhibit it (135). 
Protein kinase C may have a role (136) but the exact mechanism is still unclear. 
     
It is believed by some authors that t-PA and vWF is stored together in Weibel-Palade 
bodies (137),  but strong evidence suggests that t-PA is not stored in the Weibel-Palade 
bodies (138;139), supported by the observation that the stimulation of the release of t-
PA does not cause a simultaneous release of vWF (140;141). The exact signalling 
mechanism is unclear but G proteins and elevated intra-cellular calcium concentrations 
seem to have a role (139;142).  
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The release of t-PA also varies with the anatomic region,with more being released from 
the upper limbs than the lower limbs (143). The endothelium has a substantial capacity 
to store and release t-PA and continuous release is possible for several hours without 
significant tachyphylaxis (144;145).  
     
The main cause of death in acute coronary syndromes is due to the thrombosis that 
occurs following the rupture of an atheromatous plaque (146). Although comoonly 
present they are not usually of clinical significance (147). But if there is a disturbance in 
the equilibrium of the fibrinolytic system then the thrombus formation may continue 
leading to arterial occlusion (126). A reduction in the release or activity of t-PA in those 
with stable or unstable angina, has been linked to an increased risk of cardiac events 
(148) (149).  
     
In 2004, Lowe et al conducted a meta-analysis of twelve relevant prospective studies on 
t-Pa including their own study cohort, totalling 2119 cases of either a fatal or a non-
fatal myocardial infarction and 8832 controls (150). Their combined analysis of the 
seven studies on the general population (1669 coronary heart disease cases and 5635 
controls) yielded an odds ratio 2.18 (1.77-2.69) in those in the top third against those in 
the bottom third baseline t-Pa values. But this dropped to 1.47 (1.19-1.81) when 
adjusted for age, sex and vascular risk factors. A similar process carried out on the 
remaining six studies (based on previous vascular disease), with 450 coronary heart 
disease cases and 3197 controls revealed an adjusted odds ratio of 1.32 (0.70-2.50). 
However the authors state that despite the association shown further research was 
needed to evaluate how independent this was from established risk factors. 
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1.4.12 Von Willebrand factor 
 
Von Willebrand factor (vWF) is present in the plasma, platelets and endothelium and is 
synthesized from endiothelial cells as well as from megakaryocytes. vWF is assembled as 
high molecular weight multimers which are then cleaved by ADAMTS13, a 
metalloproteinase at specific sites in the vWF molecule to smaller units. It initiates both 
platelets adhesion and aggregation and so has an important role to play in the formation 
of thrombus (151). Following damage to the vascular endothelium vWF binds to the 
subendothelium exposed through injury, mainly collagen types I and III, triggering 
platelets adhesion to the vessel wall (151). 
     
In a meta-analysis by Whincup et al which included their own study (152) they reviewed 
a total of six studies on von Willebrand factor. This gave a total of 1524 coronary heart 
disease cases and 19,830 controls giving a combined odds ratio of 1.5 (95% CI 1.1-2.0). 
They concluded that an association existed between vWF levels and the risk of coronary 
heart disease in the future but further research was needed to assess whether this was 
causal or not. 
 
 
1.5 The acute phase response, venous thromboembolism and arterial thrombosis 
 
From its first inception venous thromboembolism (VTE) was based upon Virchow’s triad 
of stasis, changes in the vessel wall as well as thrombogenic changes. But since the 
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1970’s, there has been increasing evidence to suggest a link between VTE and 
inflammation.  
     
Under normal conditions the endothelium resists platelet adhesion, coagulation as well 
as inflammation and leucocyte activation. It manages this through: 
- the thrombomodulin production from the endothelium and protein C activation, which 
prevents excessive thrombin formation. 
- the expression of heparin and dermatan sulphate stimulating anti thrombin and 
heparin cofactor activity, again preventing excess thrombin formation. 
-  tissue factor pathway inhibitor expression (TFPI) also prevents excess thrombin 
formation. 
- tissue plasminogen activator (tPA) and urokinase-type plasminogen activator 
production locally, which stimulates fibrinolysis. 
- secretion of nitrous oxide, prostacyclin and interleukin 10 which inhibit the adhesion 
of leukocytes and platelets as well as producing vasodilatation (153). 
     
This is in contrast to when there is an endothelial disturbance, either physical from 
vascular trauma or functional as in sepsis. Here the endothelium supports a 
prothrombotic and proinflammatory state of vasoconstriction (153). This results in 
vessel vasoconstriction from the release of platelet activating factor (PAF) and 
endothelium-1 (154). Von Willebrand factor (vWF), tissue factor (TF), plasminogen 
activator inhibitor 1 (PAI-1) and coagulation factor V is also released promoting 
thrombosis (153). The endothelial cells are also stimulated to express P-selectin and E-
selectin. 
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There is emerging evidence from epidemiological studies linking VTE, arterial 
thromboembolism and atherosclerosis. The largest one of these to date by Sorensen et 
al (2007) (155) demonstrated that patients with a deep vein thrombosis also had an 
increased risk of suffering a MI (1.6) and stroke (2.6) compared to that of the control 
group population. Those with a pulmonary embolism had a higher (2.6) risk of MI and for 
stroke (2.93). The activation of inflammation and haemostasis also has a role to play in 
atherosclerosis progression, plaque rupture and arterial thrombosis (156-158).  
 
Following lower limb arthroplasty in orthopaedics, myocardial infarction is the most 
common cause of death post-operatively (159), Parvizi et al examined the records of 
over 30 000 patients who had undergone a total hip arthroplasty at their institution over 
a 30 year time period looking specifically at those patients who had died within 30 days 
of their index operation. Of the 90 who had died 21 (23%) of these were due to a 
myocardial infarction, 14 (15%) due to a fatal pulmonary embolism and only 1 (0.01%) 
patient died from a stroke. The highest incidence of deep vein thrombosis has been 
shown to occur in those following elective total hip arthroplasty (160;161). But in 
Mantilla’s paper (162) the results are subdivided into the incidence of myocardial 
infarction, pulmonary emboli and deep vein thrombosis following  total hip and knee 
replacement and also bilateral knee replacement. His results show that the incidence of 
myocardial infarction is comparable between the total hip replacement and knee 
replacement group (05% and 0.3% respectively) but is highest in the bilateral knee group 
(0.9%). Winemaker et al also confirmed that simultaneous bilateral total knee 
replacements carried significantly  higher risks post-operatively (42). A similar picture is 
seen in the incidence of deep vein thrombosis (hip 1.3%, knee 1.5%, bilateral knee 2.2%) 
and the pulmonary emboli rates (hip 0.6%, knee 0.5%, bilateral knee 1.6%). 
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Liel et al demonstrated from the Norwegian hip registry with over 67000 total hip 
arthroplasties that the 60 day post-operative mortality was 0.79%, with vascular 
diseases being the main cause of death in the early post-operative period (163). Several 
years later Lie et al performed a similar study but looked at the risks of mortality after 
both total hip and knee arthroplasty (164) but this time he combined the numbers from 
the National Joint Replacement Registry of the Australian Orthopaedic Association as 
well as the Norwegian Arthroplasty Register. The study included 81 856 patients with a 
total knee replacement and 106 254 patients with a total hip replacement. He 
demonstrated that in the first 26 days the mortality was increased at 0.187% (95% CI, 
0.168% to 0.206%), and that mortality was significantly higher in men and for those 
between their age group band of 71 to 81. They showed no significant difference in 
mortality between hip and knee arthroplasties.  
 
The Mayo Clinic (162;165) published their own results after looking at their own 
database of over 10 000 patients over a 10 year period. Their numbers included 5 233 
total hip replacements, 3 601 total knee replacements and 1 410 patients who 
underwent simultaneous bilateral knee replacements. From this, 224 patients were 
identified as having an adverse event within 30 days their surgery, which accounted for 
2.2%. Of this 0.4% had had a myocardial infarction, 0.7% a pulmonary embolism, 1.5% a 
deep venous thrombosis and 0.5% died. They also concurred with the Lie et al paper 
(164) showing that myocardial infarction was more significant in the older age group 
and in males.  
 
The possible link between venous thrombo-embolism and atherosclerosis was first 
highlighted in 2003 (158). Schulman and his associates followed up a large cohort of 
patients for up to 10 years following an acute VTE and found that a significant 
90 
 
proportion had died from either a myocardial infarction or stroke, compared to that of 
the general population (166). Hong et al (167) investigated the possible link between 
venous thrombo-embolism and coronary atherosclerotic disease. This was done by 
measuring the degree of calcification within the coronary arteries on computerised 
tomography angiographic images. They demonstrated that the degree of calcium was 
associated with VTE with and odds ratio of 4.3 (95% CI, 1.9-10.1). On a cohort of 23,796 
autopsies performed in an urban Swedish population, Eliasson et al (168) demonstrated 
an increased incidence of venous thrombo-embolism in patients with arterial thrombosis 
(odds ratio of 1.4 adjusted for age and sex; 95% CI 1.3-1.5). Therefore the evidence 
presented suggests a possible link between VTE and atherosclerosis but the exact nature 
of this association is not clear. 
     
Atherosclerosis can potentially promote the progression of thrombotic disorders (figure 
1.6). The atherosclerotic process involves platelet activation and blood coagulation. 
There is also an increased turnover of fibrin which could lead to thrombotic 
complications. They may share similar mechanisms and or risk factors (figure 1.6). 
There are several medical conditions which can give rise to both arterial and venous 
thromboembolic disorders such as side effects of chemotherapy (169) and infection 
from Chlamydia pneumoniae (170) and HIV infection (171).  
     
Studies have shown an elevation of circulatory markers of activation of inflammation, 
endothelium and coagulation in those who have or who are at risk of developing 
coronary artery disease or stroke. Fibrinogen, vWF antigen, t-PA, D-dimer and factor VII 
are all elevated in those who develop ischaemic coronary artery disease (172-177).  
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Lowe in 2006 (178) published a comprehensive review article looking at the above 
associations and stated that these associations should not imply causation and further 
work was needed to ascertain whether these associations were in his words ‘cause, 
consequence or coincidence’. From prospective case-control studies such as the 
European Concerted Action on Thrombosis deep vein thrombosis (ECAT-DVT) (179) 
showed no association with fibrinogen or factor VII, whereas the Longitudinal 
Investigation of Thromboembolism Etiology Study (LITE) (180) of clinical VTE showed 
associations with factor VII (above 95th centile), vWF but not fibrinogen. It is possible 
that the associations with fibrinogen and vWF are due to the consequences of previous 
thrombosis but this does not explain the associations with fibrinogen. On the other hand 
D-dimer has been linked with the risk of VTE both in case-control (181;182) and 
prospective studies (179;183). Whereas t-PA has no association with VTE either in case-
control (184) or prospective studies (179;185). 
  
Currently the exact role of fibrinogen in arterial thrombosis is uncertain. Although the 
meta-analysis (Fibrinogen Studies Collaboration 2005) (175) showed an association with 
coronary heart disease and stroke this was reduced once adjustment was made for 
potential confounding factors such as obesity and alcohol. This association would more 
than likely be further reduced if adjusted for socio-economic status as has been shown 
in other studies (186). The role of factor VII is not certain as studies have produced 
inconsistent results (172;187-191). 
  
D-dimer levels have an association with coronary heart disease shown both by meta-
analysis (192) and from epidemiology studies (189;191). Whereas t-PA has only a 
moderate association with coronary heart disease risk from meta-analysis (182). 
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Figure 1.6: Arterial and venous thrombosis pathophysiological links  
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1.6 Activation of blood cells studied by flow cytometry 
 
- Fluidics system 
 
In addition to the measurement of circulating levels of activation markers, systemic 
activation of blood platelets and leucocytes can be measured by flow cytometry. 
     
Flow cytometry allows the particular properties of individual particles to be measured. 
When the sample is first injected into the flow cytometer the particles for analysis are 
randomly dispersed three-dimensionally. Then through a process known as 
hydrodynamic focusing these particles are ordered into a single file. This is done by the 
drag effect caused by the faster flowing fluid that is present in an outer sheath which 
surrounds the central core into which the sample is injected. Theoretically under ideal 
conditions the central core fluid will not mix with the outer sheath fluid (figure 1.7). 
This then allows single particles to be analysed one at a time. 
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Figure 1.7: Hydrodynamic focusing producing a single stream of particles 
(reproduced with kind permission from Introduction to Flow Cytometry by Rahman, 
AbD Serotec). 
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- Optics and detection 
 
This single stream of particles then is passed through one or more beams of light 
emitted from a laser or arc lamp. The light scattering as well as the fluorescence 
emission (if labelled with a fluorochrome) gives specific information about the 
properties of the particles studied. The light can be scattered in one of two ways, 
either in a forward or at a 90o angle direction. This is then picked up by one of two lens 
known as the forward scatter channel (FSC) and the side scatter channel (SSC) 
respectively. The FSC processes information on the size of the particle but can also 
distinguish between debris and living cells and the SSC give information regarding the 
granular content. This information allows for differentiation between cells types. 
  
If labelled with a fluorochrome then fluorescence measurements can be taken at 
different wavelengths. This can give specific information on surface receptors, DNA and 
cytokines. Three main filter are used to allow the detection of specific wavelenghts: 
(Figure 1.8) 
- ‘long pass’ filters allow light above a cut-off wavelength through 
- ‘short pass’ ones allow light below a cut-off wavelength through 
- ‘band pass’ only allows light within a specified narrow range of wavelength     
    through  
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Figure 1.8: Different types of optical filters (reproduced with kind permission from 
Introduction to Flow Cytometry by Rahman, AbD Serotec). 
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These filters block light by absorption. Also as demonstrated above if the filter is placed 
at a 45o angle it becomes a dichroic filter / mirror. This means that the filters perform 
two functions, firstly they allow light of a specific wavelength to pass through in a 
forward direction and secondly they deflect the blocked light to a 90o angle.    
 
 
- Processing of the signals 
 
A small current proportional to the number of light photons is generated when they 
strike the photodetector.This is then amplified and converted to an electrical signal 
which can then be plotted. The measurement from each detector is called a 
‘parameter’ and the data in each parameter are known as ‘events’ corresponding to the 
number of cell detected. 
 
 
- Electrostatic cell sorting 
 
The main application of flow cytometry is its ability to identify and separate cells 
depending on their subtype or epitope expression. This is done through a process known 
as cell sorting or fluorescence-activated cell sorting (FACSTM) analysis. As the sample is 
orderd into single file it is passed through a beam of light. The information generated 
from the scatter and fluorescence is then compared against a set a predetermined 
criteria. If it matches then the fluid is electrically charged and passed though an 
electromagnetic field allowing the particle to be sorted (figure 1.9). 
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-  Fluorochromes and Stokes shift 
 
As mentioned previously, fluorochromes can be used to identify specific cells. 
Fluorochromes are dyes which will absorb light at a specific wavelength and releases it 
at a longer wavelength through a process known as fluorescence. As the light is 
absorbed by the fluorochrome, the electrons absorb the energy and move from its 
normal resting state to a more excited state. The amount of energy for this to happen 
will differ for each fluorochrome (shown as Eexcitation in figure 1.10). The excited states 
lasts only for 1-10 nanoseconds before the energy is released as heat and the electrons 
fall back down to a less excited state known as the ‘relaxed electronic singlet state’ 
(shown by 3 in figure 1.10) then as the electron move back to its original state the 
remaining energy is released as fluorescence (shown by Eemission in figure 1.10). 
 
 
 
 
 
 
 
 
 
 
99 
 
 
 
As this Eemission contains less energy it appears as a different colour of light to the 
Eexcitation. This difference is called the Stokes shift. 
 
Figure 1.9: Electrostatic flow sorting (reproduced with kind permission from 
Introduction to Flow Cytometry by Rahman, AbD Serotec). 
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Figure 1.10: Stokes shift (reproduced with kind permission from Introduction to 
Flow Cytometry by Rahman, AbD Serotec). 
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- Data analysis 
 
One major advantages of flow cytometry is that it can selectively visualise specific cells 
of interest through a process known as gating. Traditionally cells are gated according to 
their physical characteristics such for monocytes, granulocytes and lymphocytes 
allowing them to be distinguished from each other. 
  
On the density plot (figure 1.11), individual cell are represented by each dot or point. 
The yellow or green dots show large number of events in the population of cells. The 
colours give a three-dimensional appearance. Another way of displaying the same data 
if through the use of contour diagrams, (figure 1.11) here the joined lines represent 
similar numbers of cells.  
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Figure 1.11: Analysis of lysed whole blood using forward and side scatter 
(reproduced with kind permission from Introduction to Flow Cytometry by Rahman, 
AbD Serotec). 
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Figure 1.12: Lysed whole blood analysis using scatter and fluorescene scatter 
(reproduced with kind permission from Introduction to Flow Cytometry by Rahman, 
AbD Serotec). 
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In figure 1.12 on the left hand side is a forward and side scatter plot of lysed whole 
human blood. The lymphocytes are represented in region 1 (R1), the monocytes in 
region 2 (R2) and the granulocytes in region 3 (R3). The term ‘region’ is used to refer to 
the region in the plot which shows the data from the flow cytometer. On the graph on 
the right the same sample of lysed human whole blood has been plotted but this time 
CD45 has been added. CD45 is expressed to different degrees by all white blood cells 
but not by red blood cells. In this plot we see region 4 (R4) representing the 
lymphocytes (low SSC and high CD45 count), region 6 (R6) showing the granulocytes 
(high SSC and low CD5 count) and the monocytes in between in region 5 (R5). The main 
difference between the lymphocytes gated in region 1 and region 4  is the absence of 
red blood cells in R4. 
     
The data can also be displayed as single or double parameter histograms. A single-
parameter histogram is one that displays a single measurement such fluorescence or 
light scatter intensity on the one axis and the number of events (cell count) on the 
other (figure 1.13). 
 
 
 
 
 
 
 
 
105 
 
 
 
 
Figure 1.13: Single parameter histogram (reproduced with kind permission from 
Introduction to Flow Cytometry by Rahman, AbD Serotec). 
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This type of histogram is useful for quickly assessing the total number of events of 
inetrest. These selected cells are known as the positive dataset. 
     
The two-parameter histogram displays two measurement parameters, one on the x-axis 
and y-axis with the cell count as a density (dot) plot or contour map. The parameters 
could be SSC, FSC or fluorescence (figure 1.14). 
  
In the figure above, the lymphocytes have been stained with anti-CD3 in FITC channel 
(x-axis), and anti-HLA-DR in the PE channel (y-axis) which are markers for T cells and B 
cells respectively. Here the R2 reflects the PE-labelled B cells and R5 contains the FITC-
labelled T cells. The cells that stains for both markers are reflected in region 3 (R3) and 
finally R4 contains cells negative for both markers. 
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Figure 1.14: Two-parameter (dual-colour fluorescence) histogram (reproduced with 
kind permission from Introduction to Flow Cytometry by Rahman, AbD Serotec). 
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1.7 Polymethylmethacrylate Bone Cement 
 
Polymethylmethacrylate (PMMA) has been used in orthopaedic surgery now for over 60 
years. The word cement is often used along with PMMA but strictly speaking it is a grout 
rather than cement. As the orthopaedic speciality has advanced so has our 
understanding of its properties and it has indirectly helped enhance implant design, 
tribology and biomechanics.  
     
PMMA was first introduced in 1843 and initially known as ‘acide acrylique’ due to the 
acrid smell of the monomer (193). In 1936 it was discovered that the mixture of monomr 
and polymer gave a substance that for period a time could be moulded and 
manipulated. Its early use was in dentistry but Scales and Herschell in 1945 (194) and 
Judet and Judet in 1950 (195) used it to mould a femoral head prostheses of in the 
treatment of arthritis. It current use as a grout was first pioneered in 1953 by Haboush 
(196). The major breakthrough was when it was adapted for orthopaedic use by Sir John 
Charnley (197;198) and even now remains an integral part of modern orthopaedic 
practice. 
     
The methylmethacrylate monomer polymerises at room temperature to produce the 
solid PMMA (199). In its commercial states it consists of packs of the polymer, including 
additives (table 1.4). The molecular weight of PMMA will vary depending on the brand 
and the method of sterilisation. For instance gamma radiation for sterilisation will 
shorten the polymer chains which does not occur with ethylene oxide sterilisation (200). 
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Table 1.4: Constituents of bone cement 
Constituent Role 
Powder components  
   Polymer Polymethylmethacrylate 
   Co-polymers e.g. MM-MMA Alters physical properties of cement 
   Barium sulphate or zirconium dioxide Radio-opacifiers 
   Antibiotics  Antimicrobial prophylaxis 
   Dye e.g. chlorophyll Distinguishes cement from bone 
  
Liquid components  
   Monomer Methylmethacrylate monomer 
   N,N-dimethyl-p-toluidine (DMPT) Initiates cold curing of polymer 
   Benzoyl peroxide Reacts with DMPT to catalyse 
polymerisation 
   Hydroquinone Stabiliser to prevent premature 
polymerisation 
   Dye e.g. chlorophyll Distinguishes cement from bone 
 
 MA-MMA = methacrylate-methylmethacrylate 
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The polymerisation process is an exothermic one (201). The catalysts form free radicals 
allowing the breaking of the carbon to carbon bonds of the monomer. This can bind to 
the polymer increasing its length. This process produces heat in the order of 1.4 to 1.7 
x108 J/m3 of cement (201). This heat production has been studied both in vitro and in 
vivo (202). In vitro, the heat produced increases with higher room temperatures, an 
increased monomer to polymer ratio and when a thicker cement mantle is used (203).  
The temperatures recorded range from 70°C to 120°C and as collagen denaturing at 
temperatures above 56ºC, several authors have raised the potential risk of thermal 
damage to bone (204;205).  
      
However, lower temperatures have been sown in vivo studies (201). Reckling and Dillon 
(206) in 1977 measured the bone cement interface temperature in 20 total hip 
replacements. The maximum temperature they found was only 48°C but they attributed 
this to the possible cooling effects of the blood supply, the large surface are of a 
metallic stem and the poor thermalconduction of the cement. Others authors have 
recorded temperatures above 56°C but only for two to three minutes (207). 
     
This exothermic process already been shown to activate the complement system (208). 
Ritter et al demonstrated that the addition of polymethylmethacrylate contributes to 
the overall mortality following total hip and knee arthroplasty (209) through measuring 
levels of gamma-glutamyl-transpeptidase which was significantly elevated compared to 
a control group of hip fracture fixation using no cement. The methylmethacrylate 
monomer is an organic solvent which has been shown to be cytotoxic (210).  It may act 
on the pulmonary endothelium to enhancing the procoagulant factors already present 
adding to its hypercoagulability possibly resulting in the development of DVT (211). 
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An animal study by Dahl et al (212) compared the frequency of postoperative deep vein 
thrombosis in eight pigs who underwent a hemiarthroplasty with and without cement 
(n=16). The levels of thrombin-antithrombin complexes rose substantially during bone 
preparation followed by a rise in tissue plasminogen activator levels and a gradual fall 
in plasminogen activator inhibitor activity, with the higher rises seen in those 
undergoing a cemented prosthesis. Post-operative electron microscope scanning showed 
femoral vein thrombi in 62% of the animals in the cemented group compared to 25% in 
the uncemented group. They concluded that bone preparation during surgery induced a 
significant stimulation of the coagulation pathway and resulted in higher rates of deep 
vein thrombosis in the proximal veins, more so if cement was used for prosthesis 
fixation. 
 
 
1.8 Effect of elective general and orthopaedic surgery on inflammation and   
endothelial markers  
 
An early study by Cruickshank et al in 1990 investigated the IL-6 response to a variety of 
elective surgical procedures such as cholecystectomy, cemented total hip arthroplasty 
and major vascular surgery. They demonstrated a relationship between the duration of 
surgery and the IL-6 response (r = 0.8, p < 0.001) and concluded that IL-6 was a 
sensitive marker of tissue damage and that this response increased with greater surgical 
trauma (41). 
     
In 2000, Pape et al (172) in a prospective non randomised study investigated 105 
patients admitted to their unit for a variety of lower limb orthopaedic procedures. 
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These were then categorised into four groups. Group 1 represented a group of 
polytrauma patients with an Injury Severity Score of 18, group 2 were those with a 
isolated femoral diaphyseal fractures treated with unreamed femoral nailing, group 3 
were those with a diagnosis of osteoarthritis admitted for uncemented total hip 
arthroplasty and the final group 4 were those who had sustained an isolated ankle 
fracture for open reduction and internal fixation with a plate.  
     
The baseline values of IL-6 and TNFα were sampled from the venous circulation on skin 
incision and then at insertion of prosthesis i.e. the femoral component of a total hip 
arthroplasty, insertion of a femoral nail and the application of a plate. They found that 
the TNFα levels increased the most significantly in the group of polytrauma patients at 
all time points and although the levels increased in the total hip arthroplasty group, this 
did not reach statistical significance. The IL-6 levels showed a statistically significant 
rise at insertion of the femoral component in the total hip arthroplasty group and these 
rises were of similar magnitude to that of the femoral nailing group, showing a 
correlation between the groups (r = 5.83; p = 0.0004). 
     
The authors conceded that the study did not focus solely on skeletal operations. It also 
did not address the possibility of activation of inflammatory mediators by the 
methylmethacrylate from the bone cement used (173). 
     
Similar significant rises in IL-6 levels were also reported by Krohn et al (174) but they 
only looked at 8 adolescents (12-19 yrs) undergoing corrective surgery for thoracic 
scoliosis. The IL-6 levels were sampled from both the arterial blood as well as blood 
obtained from drains, the levels in the drained blood reaching much higher levels. Again 
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as in the previous study, several samples were taken at different time points, pre-
operatively and at 1, 2, 4 and 6 hours post-operatively. IL-6 showed a continual rise 
throughout all the sample points. 
     
They did not demonstrate a significant change in the TNFα apart from a rise during 
wound closure. They explained their results as possibly due to its short biological half-
life. Others have also shown no significant rises in the TNFα levels in the case of total 
hip arthroplasties (213;214) but Andres et al demonstrated significant levels of local 
TNFα in surgical drains post-operatively (215). 
     
Other studies have looked into the effects of total knee arthroplasty on monocytes-
platelet expression as well as the expression of CD40L on platelets, using flow 
cytometry. Kageyama et al (175) recruited 24 patients into their study who were then 
randomised into two groups, one with and the other without the use of a tourniquet 
intra-operatively. Two patients (one from each group) were excluded due to 
anaesthetic difficulties resulting in the operation being cancelled. The remaining 22 
subjects had venous and arterial blood sampled before and at the end of surgery. 
Samples were also taken 6 hours then again at 24 hours following surgery. They found 
that monocytes-platelet expression levels peaked at around 2.5 hours following skin 
incision and then returned to baseline levels at 24 hours. A similar picture was also seen 
in CD40 expression with a maximal change of around 25% from baseline levels. They 
found that circulating levels of sCD40L increased in proportion with levels obtained by 
flow cytometry (p<0.05). These results were increased in the group with tourniquet 
inflation, however the authors failed to mention if this was statistically significant or 
not. The authors concluded that their results after total knee arthroplasty may highlight 
an important role for blood cell activation in the pathogenesis of hypercoagulability and 
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venous thrombosis. But the numbers of this study are small (n=22) and although an 
attempt was made to look at the difference with the use of an inflated tourniquet no 
mention is made as to whether their differences seen were statistically significant but 
he went on to state that his results support the hypothesis that the use of a tourniquet 
causes the retention of blood flow, increases the coagulation activity as well as 
disrupting the vascular endothelium contributing to venous thrombosis. This hypothesis 
is supported by several smaller studies (216-218).  
 
There is more evidence for elective cemented total hip arthroplasty as previous studies 
have demonstrated an increase in the thromboplastin activity of monocytes (219). Dahl 
et al (220) showed that the thromboplastin activity was confined to the cell surface of 
the monocytes where fibrin formation occurred. This in turn may contribute to the 
increased coagulability that is induced when blood passes the lung (221). These 
pericellular fibrin deposits may allow the monocytes to attach to the vessel walls 
promoting thrombus formation. This may occur more so in an environment where the 
endothelial surface is already stimulated due to local mechanical, chemical (bone 
cement) or biochemical factors. As well as this the activated monocytes may have an 
increased expression of cell surface adhesion molecules e.g. selectins. Therefore this 
may contribute to the higher frequency of DVT observed in patients receiving cemented 
hip prostheses (160).  
     
Another study also looked at the levels of CD40L and expression of monocytes-platelets 
but in subjects undergoing cemented total hip arthroplasty. Ray et al (74) recruited 45 
subjects. Their aim was to look at a possible link between CD40L expression and 
cardiovascular complications 30 days following surgery. Sampling was taken through an 
arterial line before and then one hour following completion of surgery for flow 
115 
 
cytometry analysis. The recorded adverse cardiovascular events were two patients with 
non-ST elevation myocardial infarction (NSTEMI), two with atrial fibrillation and another 
two patients with both and NSTEMI and atrial fibrillation. They found that these 6 
patients compared to those with no complications (n=39) were more likely to be 
diabetic (2/6 versus 1/39, p=0.04) and had a past medical history of cardiovascular 
disease (3/6 versus 4/39, p=0.04). Flow cytometry revealed that the CD40L expression 
on platelets before surgery was a median of 11% (IQR 7.9-12.8) in patients with a history 
of cardiovascular disease compared to 4.7% (IQR 1.9-6.6) for those with none (p=0.001). 
The increase in CD40L expression in both groups at one hour post procedure was 
statistically significant. 
     
Bagry et al looked at the effect on the inflammatory response of a continuous 
peripheral nerve block following a primary total knee arthroplasty in 12 patients (222). 
All underwent a spinal anaesthetic and were then randomized to either patient-
controlled analgesia using morphine (n =6) or lumbar plexus and sciatic nerve blocks 
with ropivacaine (0.2%) for 48 hours. Venous blood was sampled at specific time points 
up to 48 hours post-operatively. They found that both leucocyte and CRP levels were 
significantly lower in those with the continuous nerve block, which therefore 
attenuated the inflammatory response. The reduction in the inflammatory response can 
improve the functional recovery by reducing the injury-induced immunosuppression 
(223) with prolonged elevation of CRP and IL-6 following hip arthroplasty being 
associated with poor mobilisation and rehabilitation. Other have carried out similar 
studies with epidural anaesthesia but have not found a significant reduction in the 
inflammatory response (224) which Bagry et al stated was due to the blocking of both 
the afferent and efferent fibres innervating the surgical area, preventing primary and 
secondary hyperalgesia which is not possible with epidural anaesthesia. Bagry et al did 
however concede that the systemic effect of the local anaesthetic could not be 
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excluded as research has demonstrated that the use of local anaesthetics either given 
locally or systemically will affect the inflammatory response in animals (225). However 
the local attenuation of the inflammatory response has been shown in vitro by Su et al 
(49). 
  
From this review of the current literature it appears that elective orthopaedic surgery 
including total knee arthroplasty does activate inflammation, endothelium and blood 
coagulation, as measured both by circulating levels of activation markers and by flow 
cytometry. These effects may be influenced by the use of bone cement, by local 
anaesthetic infiltration intra-operatively or the use of post-operative drains and may 
also be related to the increased post-operative risks of arterial and venous thrombosis. 
  
To date no systematic study has been reported comparing the effects of bone cement, 
local anaesthetic infiltration and post-operative drains in elective total knee 
arthroplasty. 
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AIM 
 
The aim of the studies reported in this thesis is to examine and compare the effects of 4 
different aspects of elective orthopaedic total knee arthroplasty on the activation of 
selected circulating markers of inflammation, endothelium, coagulation and fibrinolysis: 
 
- IL-6   inflammatory cytokine 
- TNFα   inflammatory cytokine 
- CRP   sensitive inflammatory marker 
- e-selectin  endothelial marker 
- sCD40L  general marker of inflammation 
- tPA    endothelial marker 
- vWF   endothelial marker 
 
As well as this I will study the effects of the 4 aspects of elective orthopaedic total knee 
arthroplasty on blood cell activation of selected cytokines: 
 
- expression of CD40 on monocytes 
- expression of the CD14 / CD42a dyad on monocytes 
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Four study groups will be compared: 
 
1) Patients undergoing elective uncemented total knee arthroplasty 
 
2) Patients undergoing elective cemented total knee arthroplasty, to investigate any 
additional response to the exothermic reaction of the PMMA cement. 
 
3) Patients undergoing uncemented total knee arthroplasty, with local infiltration of 
local anaesthetic intra-operatively. 
 
4) Patients undergoing uncemented total knee arthroplasty, with the use of a drain 
post-operatively 
 
In order to quantify the effect of the use of cement, intra-operative local anaesthetic 
infiltration or a drain I will be comparing the following groups: 
 
1) Cemented group versus uncemented group to assess any additional effect the cement 
may have on the inflammatory or endothelial response. 
 
2) Uncemented group versus the group with local anaesthetic infiltration to assess 
whether the local anaesthetic would dampen the inflammatory and endothelial 
response. 
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3) Uncemented group versus the group with a surgical drain to assess any effect this 
would have on the inflammatory and endothelial response. 
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CHAPTER 2 
 
SUBJECTS AND METHODS 
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2.1 Subjects 
 
All patients attending Monklands Hospital assessed for an elective cemented or 
uncemented total knee arthroplasty were identified. They were then approached at the 
pre-assessment clinic (which routinely took place a week before their intended 
operation date) by the author where the study was explained to them, and they were 
invited to take part in the study. After informed consent was obtained a patient history 
was taken which included the history of the presenting complaint, past medical history, 
drug and social history. The patient’s case notes were then reviewed and if they were 
eligible for the study they were recruited at that point. (Table 2.1) Following 
recruitment into the study, patients were excluded if they developed a post-operative 
infection confirmed by bacteriological sampling. 
 
As part of the consent, subjects were told that the average length of hospital stay 
following a total knee arthroplasty was around 5 to 7 days. This meant that usually by 
the time the last blood sample was due to be taken, there would a high likelihood that 
they would have been discharged home. So subjects were only enrolled into the study if 
they agreed to a home visit by the author at day 7 post operation in order to obtain the 
third and final sample. 
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Table 2.1: Inclusion criteria for the study 
 
Subjects were recruited into the study if they met all the following 
requirements: 
- no history of uncontrolled hypertension 
- no history of ischaemic heart disease 
- were able to give informed consent in the opinion of the researcher 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
An information sheet (Annex 1) outlining the study along with contact details was given 
to the subject and a copy of the information sheet was attached to the patient’s 
casenotes to indicate their participation. A cover letter (Annex 2) and information sheet 
was sent to their general practitioner. Ethical approval (Annex 3) was obtained from the 
Local Research Ethics Committee. 
 
The subjects were admitted into the elective orthopaedic ward at Monklands Hospital 
the day before their surgery. They were approached by the author and any questions 
that had arisen from the previous consultation were addressed. As well as this, a pre-
operative electrocardiogram was taken. 
  
The day after their total knee replacement (day 1 post-operation) the second set of 
blood samples were taken as pre-operatively. A record was also taken of the 
anaesthetic sheet to note the blood pressure readings during the time of surgery and a 
post-operative electrocardiogram was done. 
     
At day 7 post total knee arthroplasty if the subject was still in the ward the final set of 
blood samples were taken as pre-operatively. If they had been discharged home the 
subject was contacted at home and a suitable time was agreed for the author to visit 
and take the final samples. 
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2.2 Blood sampling, handling and laboratory assays 
 
Following enrolment into the study the first of three sets of blood sample was taken. 
These pre-operative blood samples were collected in the BD Vacutainer system. (Table 
2.2) Two BD Vacutainers, SST II Advance (yellow top bottles) were taken and sent to the 
biochemistry laboratory for routine urea and electrolytes, liver function tests, 
cholesterol and C-reactive protein. One BD Vacutainer, K3E 7.2mg EDTA (purple top 
bottle) was sent to the haematology laboratory for a full blood count as well as for a 
differential white cell count, and one BD Vacutainer, 9NC 0.109M trisodium citrate 
(light blue top bottle) for coagulation profile. A further two EDTA bottles were taken for 
flow cytometry analysis and one citrate and a SST bottle for the endothelial markers. 
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Table 2.2: Overview of BD Vacutainer systems 
 
Colour of 
bottle top 
Volume 
(ml) 
System Additives 
Yellow 5 BD Vacutainer, SST II 
Advance 
Spray coated silica and polymer 
gel for serum separation 
Purple 4 BD Vacutainer, K3E 
7.2mg EDTA 
Spray coated K3 EDTA – 
anticoagulant 
Light Blue 2.7 BD Vacutainer, 9NC 
0.109M 
3.2% buffered trisodium citrate 
anticoagulant 
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The samples for flow cytometry were taken directly to the Haematology laboratory. The 
peripheral blood was labelled with combinations of FITC-conjugated anti CD14; PE-
conjugated anti CD42a and PE-conjugated and anti CD40 (AbD Serotec, Kidlington, UK). 
After incubation red cells were lysed using EasyLyse ammonium chloride RBC lysing 
solution (Dako,Denmark). Data acquisition and analysis was performed on a FACS Canto 
II flow cytometer (Becton Dickinson, San Jose, CA). Monocytes were identified from 
light scatter properties and a gate applied. 10000 events within the monocyte gate were 
collected. Number of gated events, mean fluorescence intensity and percentage 
positive events were recorded. Isotype FITC and PE controls were analysed on each 
sample to determine background fluorescence. All samples were processed within 24-
48hrs.     
 
The citrate and SST bottles were also taken to the Haematology laboratory where they 
were centrifuged at 1500g for 10 minutes. The plasma was then separated as follows: 
- plasma from the citrate bottle was decanted into two 1 ml aliquots 
- serum was decanted into two 1 ml aliquots 
 
The samples were then stored in a -40°C degree freezer. All samples were centrifuged 
and stored within three hours of venepuncture. All samples were stored in the freezer 
until such time that they could be transferred by the author to the University 
Department of Medicine laboratory at Glasgow Royal Infirmary for analysis. 
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Soluble CD40 ligand (sCD40L), e-selectin and interleukin 6 (IL6) were assayed by high-
sensitivity enzyme-linked immunoasorbent assay (ELISA) kits from R&D systems, Oxford, 
United Kingdom. 
 
Plasma von Willebrand factor (vWF) antigen levels were measured with an in-house 
enzyme linked immunoasorbent assay (ELISA), using rabbit anti-human polyclonal 
antibodies (DAKO plc, High Wycombe, UK). Tissue plasminogen activator levels were 
measured with a commercially available enzyme-linked immunoasorbent assay (ELISA) 
(Trinity Biotech, Sulhampstead, UK).  
 
In the laboratory the intra- and inter-assay coefficient of variations (CV) for IL6 was 
7.5% and 8.9% respectively, 4.2% and 3.3% for vWF, 6.6% and 6.5 % for tPA, 5.9% and  
8.6% for e-selectin, ~12.6% for TNFα and ~6.0% for sCD40L. 
 
 
2.3 Statistical Analysis 
 
A Shapiro-Wilk test was done to test for normaility. All variables except for the CD40, 
CD1442a and e-selectin count were normally distributed.  For the parametric data 
results are presented as mean, SD and SEM. Differences between the three time points 
(pre-operative, day 1 and day 7) were analysed using pair sampled t-tests. This was 
done for all the four groups. Independent sample t-tests were used to look for 
differences between groups. The non-parametric data results are presented as median 
and IQR. The differences between the three time points were analysed using Wilcoxon 
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signed rank tests. Mann-Whitney U tests were used to look for differences between the 
groups. 
 
Advice on statistical analyses was sought from the Robertson Centre for Biostatistics, 
The University of Glasgow. 
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Chapter 3 
 
The effect of elective uncemented total knee 
arthroplasty on the activation of markers of 
inflammation, endothelium and coagulation 
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3.1 Subject Characteristics 
 
There were 20 patients recruited into this study, one patient developed a post-
operative deep wound infection with positive wound cultures. This required a second 
procedure in the form of a wound washout and exchange of the polyethylene liner and 
was therefore removed from the study, leaving 19 patients. The mean body mass index 
(BMI) was 30.3kg/m2, standard deviation 5.1. There were 10 males (mean age 65.3 
years, standard deviation 7.36) and 9 females (mean age 67.8 years, standard deviation 
8.97). A total of 6 total knee arthroplasties were carried out on the left and 13 on the 
right. 
 
 
3.2 Blood cell count and CRP 
 
The mean values, standard deviations and standard error of means of blood cell counts 
and CRP are summarised in table 3.1. 
 
Each of these variables were compared over three time periods, from pre-operative 
values to day 1 post-operation (P1-D1), from day 1 to day 7 post-operation (D1-D7) and 
from pre-operative to day 7 post-operation (P1-D7). 
 
There were significant changes at all three time points for the platelets (Plat) (Figure 
3.1), white cell count (WCC) (Figure 3.2) and neutrophils (Neutro) (Figure 3.3), with an 
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initial rise then fall except for the platelets which had an initial fall in their levels. The 
monocytes (Mono) (Figure 3.4) also had a significant rise but just failed to reach 
significance when their levels dropped at day 7. C-reactive protein (CRP) showed a 
significant rise in the first 24 hours and remained significantly elevated at day 7 (Figure 
3.5). 
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Table 3.1: Mean, standard deviations and standard error of means of platelets (Plat), 
white cell count (WCC), neutrophils (Neutro), monocytes (Mono) (all 109/L) and C-
reactive protein (CRP) (mg/L) pre-operatively (P1) and at day 1 (D1) and day 7 (D7) 
post-operatively in the uncemented total knee arthroplasty group (n=19) 
 
 Mean Standard Deviation Standard Error of Mean 
Plat P1 260 71 16 
Plat D1 204 57 13 
Plat D7 333 79 18 
WCC P1 8.1 1.5 0.3 
WCC D1 9.9 2.2 0.5 
WCC D7 8.9 2.1 0.5 
Neutro P1 4.7 1.1 0.2 
Neutro D1 7.3 1.9 0.4 
Neutro D7 5.8 2.0 0.4 
Mono P1 0.6 0.2 0.1 
Mono D1 1.1 0.5 0.1 
Mono D7 0.8 0.3 0.1 
CRP P1 2 3 1 
CRP D1 68 38 9 
CRP D7 67 31 7 
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Table 3.2: Paired sample t-test of platelets, WCC, neutrophils, monocytes and CRP 
in the uncemented total knee arthroplasty group (n=19) 
 
  Mean Standard Deviation P value 
Plat P1-D1 55 33 <0.01 
 D1-D7 -129 51 <0.01 
 P1-D7 -73 53 <0.01 
WCC P1-D1 -1.8 1.9 <0.01 
 D1-D7 1 2.0 0.05 
 P1-D7 -0.8 1.5 0.02 
Neutro P1-D1 -2.6 1.8 <0.01 
 D1-D7 1.4 2.2 0.01 
 P1-D7 -1.2 1.6 <0.01 
Mono P1-D1 -0.5 0.4 <0.01 
 D1-D7 0.4 0.4 <0.01 
 P1-D7 -0.1 0.3 0.07 
CRP P1-D1 -66 38 <0.01 
 D1-D7 0.5 52 0.97 
 P1-D7 -65 30 <0.01 
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Figure 3.1: Graph of changes in platelet levels (x109/L) over the three time points (mean and 
standard deviation) in the uncemented total knee arthroplasty group (n=19) 
 
Figure 3.2: Graph of changes in white cell count levels (x109/L) over the three time points 
(mean and standard deviation) in the uncemented total knee arthroplasty group (n=19) 
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Figure 3.3: Graph of changes in neutrophil levels (x109/L) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group (n=19) 
 
Figure 3.4: Graph of changes in monocyte levels (x109/L) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group (n=19) 
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Figure 3.5: Graph of changes in C-reactive protein levels (mg/L) over the three time points 
(mean and standard deviation) in the uncemented total knee arthroplasty group (n=19) 
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3.3 Circulating activation markers 
 
The mean, standard deviations and standard error of means of tissue plasminogen 
activator (t-PA), Von Willebrand factor (vWF), soluble CD40 ligand (sCD40L), interleukin 
6 (IL6), tumour necrosis factor (TNFα) and e-selectin are summarised in table 3.3. 
 
Each variable was then compared over the three time points from pre-operative values 
to day 1 post-operation (P1-D1), from day 1 to day 7 post-operation (D1-D7) and from 
pre-operative to day 7 post-operation (P1-D7) (Table 3.4). 
 
The t-PA levels showed a non-significant rise in the first 24 hours (p=0.06) but by day 7 
there was a significant rise from the pre-operative levels (p=0.01) (Figure 3.6). The vWF 
levels rose significantly in the first 24 hours (p=0.00) and remained higher at day 7 
(Figure 3.7). The sCD40L showed a significant fall from pre-operative levels and rose 
from day 1 levels to day 7 (p=<0.01) (Figure 3.8). IL 6 rose and fell significantly (Figure 
3.9). TNFα rose significantly at day 7 (Figure 3.10). The e-selectin levels did not show 
any significant changes at any of the time points (Figure 3.11). 
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Table 3.3a: Mean, standard deviations and standard error of means of tissue 
plasminogen activator (t-PA) (ng/ml), von Willebrand factor (vWF) (IU/dl), soluble 
CD40 ligand (sCD40L) (pg/ml), interleukin 6 (IL6) (pg/ml) and tumour necrosis factor 
(TNFα) (pg/ml) in the uncemented total knee arthroplasty group (n=19) 
 
 Mean Standard Deviation Standard Error Mean 
t-PA P1 11.5 4.5 1.1 
t-PA D1 14.4 6.0 1.4 
t-PA D7 15.1 7.1 1.7 
vWF P1 119 38 9. 
vWF D1 197 73 18 
vWF D7 206 45 11 
sCD40L P1 3300 2020 476 
sCD40L D1 2803 2227 525 
sCD40L D7 4282 2417 570 
IL6 P1 4.3 2.6 0.6 
IL6 D1 173.3 113.9 26.8 
IL6 D7 31.9 47.9 12.0 
TNFα P1 1.8 0.8 0.3 
TNFα D1 2.2 1.0 0.3 
TNFα D7 2.3 1.0 0.3 
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Table 3.3b: Median and Inter-quartile ranges (IQR) of e-selectin (ng/ml) in the 
uncemented total knee arthroplasty group (n=19) 
 
  Percentiles 
25th 50th (Median) 75th 
E-selectin P1 15.5 
 
24.5 35.1 
 D1 15.0 26.2 29.1 
 P1 13.7 23.9 27.1 
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Table 3.4a: Paired sample t-test of tissue plasminogen activator (t-PA) (ng/ml), von 
Willebrand factor (vWF) (IU/dl), soluble CD40 ligand (sCD40L) (pg/ml), interleukin 6 
(IL6) (pg/ml) and tumour necrosis factor (TNFα) (pg/ml) in the uncemented total 
knee arthroplasty group (n=19) 
 
  Mean Standard Deviation P value 
t-PA P1-D1 -2.8 6.0 0.06 
 D1-D7 -0.8 7.1 0.65 
 P1-D7 -3.61 5.31 0.01 
vWF P1-D1 -77 71 <0.01 
 D1-D7 -9 69 0.60 
 P1-D7 -82 38 <0.01 
sCD40L P1-D1 497 2047 0.32 
 D1-D7 -1480 1973 <0.01 
 P1-D7 -983 1735 0.03 
IL6 P1-D1 -169.0 113.4 <0.01 
 D1-D7 146.2 139.2 <0.01 
 P1-D7 -27.8 48.0 0.03 
TNFα P1-D1 -0.4 0.8 0.13 
 D1-D7 -0.1 0.9 0.69 
 P1-D7 -0.5 0.3 <0.01 
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Table 3.4b: Wilcoxon signed rank test for e-selectin (ng/ml) in the uncemented total 
knee arthroplasty group (n=19) 
 
  P-value 
E-selectin P1-D1 0.20 
 D1-D7 0.94 
 P1-D7 0.09 
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Figure 3.6: Graph of changes in tissue plasminogen activator levels (ng/ml) over the three 
time points (mean and standard deviation) in the uncemented total knee arthroplasty group 
(n=19) 
 
Figure 3.7: Graph of changes in von Willebrand factor levels (IU/dL) over the three time 
points (mean and standard deviation) in the uncemented total knee arthroplasty group 
(n=19) 
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Figure 3.8: Graph of changes in soluble CD40 ligand levels (pg/ml) over the three time points 
(mean and standard deviation) in the uncemented total knee arthroplasty group (n=19) 
 
 
Figure 3.9: Graph of changes in soluble interleukin 6 levels (pg/ml) over the three time 
points (mean and standard deviation) in the uncemented total knee arthroplasty group 
(n=19) 
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Figure 3.10: Graph of changes in tumour necrosis factor alpha levels (pg/ml) over the three 
time points (mean and standard deviation) in the uncemented total knee arthroplasty group 
(n=19) 
 
 
Figure 3.11: Graph of changes in soluble e-selectin levels (ng/ml) over the three time points 
(median and interquartile ranges) in the uncemented total knee arthroplasty group (n=19) 
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3.4 Flow cytometry assays of cell cytokine expression 
 
The mean, standard deviations and standard error of means of the CD1442a and CD40 
flow cytometry values are summarised in table 3.5. The values are described both in 
absolute values (number of cell counts) and in percentages.  
  
The flow cytometry readings were also analysed at the three times points using paired 
sampled t-tests (table 3.6). The analysis was carried using both the absolute values and 
chi squared tests for percentage values. The only statistically significant change was 
seen in the CD40 from the pre-operative levels (P1) to the day 1 (D1) post-operative 
levels when looking at both the absolute numbers and percentage changes (p= 0.01 and 
0.004 respectively), (Figure 3.12). No significant changes were seen with the CD1442a 
levels (Figure 3.13). 
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Table 3.5a: The mean, standard deviation and standard error of means of CD1442a 
and CD40, expressed as percentage values in the uncemented total knee 
arthroplasty group (n=19) 
 
 Mean Standard Deviation Standard Error Mean 
CD1442a percent P1 6.4 6.3 1.4 
CD1442a percent D1 6.7 6.1 1.4 
CD1442a percent D7 7.6 7.5 1.7 
CD40 percent P1 0.8 0.7 0.2 
CD40 percent D1 0.3 0.3 0.1 
CD40 percent D7 1.2 0.8 0.2 
  
 
 
 
 
 
 
 
 
 
 
147 
 
Table 3.5b: Median and Inter-quartile ranges (IQR) of CD1442a and CD40, expressed 
as absolute values in the uncemented total knee arthroplasty group (n=19) 
 
  Percentiles 
25th 50th (Median) 75th 
CD1442a P1 254 456 1362 
 D1 185 492 1006 
 P7 158 352 1250 
CD40 P1 20 50 146 
 D1 10 32 54 
 P7 62 89 200 
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Table 3.6a: Mean, standard deviation and p values of CD1442a andCD40 (mean and 
SD) in the uncemented total knee arthroplasty group (n=19) 
 
  Mean Standard deviation P value 
CD1442a 
percentage 
P1-D1 -0.4 3.9 0.67 
D1-D7 -0.9 5.6 0.50 
P1-D7 -1.2 5.4 0.33 
CD40 
percentage 
P1-D1 0.4 0.5 0.04 
D1-D7 -0.8 0.6 <0.01 
P1-D7 -0.4 0.7 0.21 
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Table 3.6b: Wilcoxon signed rank test for CD1442a andCD40 in the uncemented 
total knee arthroplasty group (n=19) 
 
  P-value 
CD1442a P1-D1 0.33 
 D1-D7 0.86 
 P1-D7 0.81 
CD40 P1-D1 0.01 
 D1-D7 0.01 
 P1-D7 0.16 
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Figure 3.12: Graph of changes in CD40 counts over the three time points (median and 
interquartile ranges) in the uncemented total knee arthroplasty group (n=19) 
 
 
Figure 3.13: Graph of changes in CD1442a counts over the three time points (median and 
interquartile ranges) in the uncemented total knee arthroplasty group (n=19) 
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3.5 Discussion 
 
The transient rise in the white cell count, neutrophils, monocytes and platelets supports 
the existing literature on the acute phase response following surgery (226). 
     
The CRP levels responded mainly in the first 24 hours and even at 7 days remained 
significantly risen reflecting the ongoing surgical stimulus. This may be predominantly 
due to the continued high levels of IL6 which remained significantly elevated throughout 
the 7 days reflecting the ongoing inflammatory process. The IL6 levels reflect the 
degree of surgical trauma (40) and in most instances the secretion of IL6 is brief and 
self-limiting lasting from 48-72 hours (41) but this demonstrates that the stimulus of the 
surgical trauma continues at least up to 7 days post-operatively.  
 
Following the surgical trauma to the tissues and vessels the vascular endothelium 
becomes procoagulant with the release of several factors including vWF. In response to 
the thrombus formation t-PA is released from the endothelium (127) and our results 
reflect this with significant levels of both vWF and t-PA in the first 24 hours with levels 
remaining significantly elevated to at least 7 days. 
     
The TNFα levels are significant at day 7 possibly reflecting the ongoing inflammatory 
response and its role in initiating the cytokine cascade, increasing vascular permeability 
and in recruiting macrophages and neutrophils. The e-selectin levels did not 
demonstrate a significant change in this study. 
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The CD40 expression showed a significant change from the pre-operative levels up to 
day 7 post-operatively. This reflects the release from the endothelium in the vessels 
within the inflamed tissue in the operative field (84).But the CD1442a changes remained 
insignificant. 
 
It is not possible to compare these results to the current literature as there has not 
been a study to date to allow a direct comparison. There have been several studies that 
have looked at the CRP and IL6 response following trauma (41;227) but these have been 
in heterogeneous groups comprising of general surgical as well as orthopaedic cases and 
the orthopaedics cases included trauma as well other elective cases such as ankle 
fixation and total hip replacements. This study does show a significant rise in the TNFα 
levels at day 7, the current literature has demonstrated that no significant changes 
occur but these studies were only carried out on those undergoing a total hip 
replacement (213;214).  
 
No comparison is possible in terms of the CD40 and CD1442a changes as no study has 
specifically looked at these following either total hip or total knee replacement. 
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CHAPTER 4 
 
The effect of elective cemented total knee 
arthroplasty on the activation of markers of 
inflammation, endothelium and coagulation 
 
 
 
 
 
 
154 
 
4.1 Subject characteristics 
 
There were 20 patients recruited into this study, one patient was subsequently excluded 
due to a deep vein thrombosis confirmed on ultrasound leaving 19 patients in this 
cohort. The patient was excluded as the deep vein thrombosis would have contributed 
to the inflammatory response. The mean body mass index (BMI) was 30.5kg/m2, 
standard deviation 5.2. There were 6 males (mean age 60.3 years, standard deviation 
12.74) and 13 females (mean age 70.7 years, standard deviation 8.57). A total of 9 total 
knee arthroplasties were carried out on the left and 10 on the right. None of these 
characteristics was significantly different from the uncemented group in Chapter 3. 
 
 
4.2 Blood cell counts and CRP 
 
The mean values and standard deviations and standard error of mean of white cell 
count (WCC), neutrophils (Neutro), monocytes (Mono) and C-reactive protein (CRP) are 
summarised in table 4.1. 
 
Each of these variables were compared over three time periods, from pre-operative 
values to day 1 post-operation (P1-D1), from day 1 to day 7 post-operation (D1-D7) and 
from pre-operative to day 7 post-operation (P1-D7), the results of which are 
summarised in table 4.2. The paired sample t-tests revealed a significant decrease then 
increase for the platelet count (Figure 4.1) and a significant increase then decrease for 
the white cell count (Figure 4.2). Neutrophils (Figure 4.3), monocytes (Figure 4.4) and 
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C-reactive protein (CRP) levels (Figure 4.5) showed a significant rise in the first 24 hour 
period and remained significantly elevated at day 7. 
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Table 4.1 :  Mean, standard deviations and standard error of means of platelets, 
white cell count (WCC), neutrophils (Neutro), monocytes (Mono) (all 109/L) and C-
reactive Protein (CRP) (mg/L) pre-operatively (P1) and on days1 (D1) and day 7 (D7) 
post-operatively in the cemented total knee arthroplasty group (n=19) 
 
 Mean Standard Deviation Standard Error Mean 
Plat P1 241 32 8 
Plat D1 210 61 14 
Plat D7 299 109 26 
WCC P1 7.5 1.4 0.3 
WCC D1 8.8 2.3 0.5 
WCC D7 7.6 1.9 0.4 
Neutro P1 5.0 1.7 0.4 
Neutro D1 6.3 2.2 0.5 
Neutro D7 5.3 1.6 0.4 
Mono P1 0.5 0.1 0.03 
Mono D1 0.9 0.4 0.1 
Mono D7 0.6 0.2 0.05 
CRP P1 1.5 1.8 0.4 
CRP D1 71 36 9 
CRP D7 86 66 15 
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Table 4.2: Paired sample t-tests of WCC, neutrophils, monocytes and CRP in the 
cemented total knee arthroplasty group (n=19) 
 
  Mean Standard Deviation P value 
Platelets P1-D1 31 54 0.02 
 D1-D7 -89 70 <0.01 
 P1-D7 -58 97 0.02 
WCC P1-D1 -1.3 2.0 0.01 
 D1-D7 1.1 2.4 0.06 
 P1-D7 -0.2 1.5 0.66 
Neutro P1-D1 -1.3 2.0 0.01 
 D1-D7 1.0 2.4 0.08 
 P1-D7 -0.3 1.2 0.36 
Mono P1-D1 -0.4 0.4 <0.01 
 D1-D7 0.3 0.4 <0.01 
 P1-D7 -0.1 0.2 0.08 
CRP P1-D1 -70 
 
36 <0.01 
 D1-D7 -14 71 0.41 
 P1-D7 -84. 66 <0.01 
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Figure 4.1: Graph of changes in platelet count (x109/L) over the three time points (mean and 
standard deviation) in the cemented total knee arthroplasty group (n=19) against the 
uncemented total knee arthroplasty group (n=19) 
 
Figure 4.2: Graph of changes in white cell count (x109/L) over the three time points (mean 
and standard deviation) in the cemented total knee arthroplasty group (n=19) against the 
uncemented total knee arthroplasty group (n=19) 
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Figure 4.3: Graph of changes in neutrophil count (x109/L) over the three time points (mean 
and standard deviation) in the cemented total knee arthroplasty group (n=19) against the 
uncemented total knee arthroplasty group (n=19) 
 
Figure 4.4: Graph of changes in monocyte count (x109/L) over the three time points (mean 
and standard deviation) in the cemented total knee arthroplasty group (n=19) against the 
uncemented total knee arthroplasty group (n=19) 
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Figure 4.5: Graph of changes in C-reactive protein (mg/L) over the three time points (mean 
and standard deviation) in the cemented total knee arthroplasty group (n=19) against the 
uncemented total knee arthroplasty group (n=19) 
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4.3 Circulating activation markers 
 
The mean, standard deviations and standard error of means of tissue plasminogen 
activator (t-PA), von Willebrand factor (vWF), soluble CD40 ligand (sCD40L), interleukin 
6 (IL6), tumour necrosis factor (TNFα) and e-selectin are summarised in table 4.3. 
 
Each variable was then compared over the three time points (Table 4.4). The t-PA levels 
showed a non-significant rise initially but did become significant at day 7 post-
operatively (p=0.04) (Figure 4.6). The vWF levels showed similar changes becoming 
significant after 24 hours and remaining so at day 7 (<0.01) (Figure 4.7). The sCD40L 
levels were significantly lower by 24 hours and remained so at day 7 (Figure 4.8). The 
IL- 6 levels rose and fell significantly (Figure 4.9). TNFα levels did not initially show a 
significant rise but by day 7 their levels had significantly risen compared to the pre-
operative (Figure 4.10). E-selectin levels fell significantly by day 7 (Figure 4.11). 
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Table 4.3a: Mean, standard deviations and standard error of means of tissue 
plasminogen activator (t-PA) (ng/ml), von Willebrand factor (vWF) (IU/dl), soluble 
CD40 ligand (sCD40L) (pg/ml), interleukin 6 (IL6) (pg/ml) and tumour necrosis factor 
(TNFα) in the cemented total knee arthroplasty group (n=19) 
 
 Mean Standard Deviation Standard Error Mean 
t-PA P1 12.3 2.4 0.7 
t-PA D1 14.8 5.9 1.9 
t-PA D7 17.4 6.9 2.1 
vWF P1 153 72 19 
 
vWF D1 187 68 18 
vWF D7 233 60 15 
sCD40L P1 4243 2594 693 
sCD40L D1 3052 2366 632 
sCD40L D7 4638 2076 536 
IL6 P1 4.5 2.3 0.6 
IL6 D1 189.2 160.1 41.3 
IL6 D7 61.3 80.0 20.0 
TNFα P1 2.7 0.7 0.3 
TNFα D1 3.5 1.3 0.6 
TNFα D7 3.7 1.0 0.5 
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Table 4.3b: Median and Inter-quartile ranges (IQR) of e-selectin (ng/ml) in the 
cemented total knee arthroplasty group (n=19) 
 
  Percentiles 
25th 50th (Median) 75th 
E-selectin P1 23.8 35.8 46.5 
 D1 21.3 30.3 35.3 
 P1 23.88 30.3 34.3 
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Table 4.4a: Paired sample t-test of tissue plasminogen activator (t-PA) (ng/ml), von 
Willebrand factor (vWF) (IU/dl), soluble CD40 ligand (sCD40L) (pg/ml), interleukin 6 
(IL6) (pg/ml) and tumour necrosis factor (TNFα) (pg/ml) in the cemented total knee 
arthroplasty group (n=19) 
 
  Mean Standard Deviation P value 
t-PA P1-D1 -2.5 5.6 0.20 
 D1-D7 -2.8 7.0 0.22 
 P1-D7 -4.0 5.4 0.04 
vWF P1-D1 -35 64 0.56 
 D1-D7 -47 43 <0.01 
 P1-D7 -80 67 <0.01 
sCD40L P1-D1 1191 1939 0.04 
 D1-D7 -1543 2031 0.01 
 P1-D7 -318 1556 0.46 
IL 6 P1-D1 -184.6 159.5 <0.01 
 D1-D7 141.8 203.8 0.01 
 P1-D7 -56.6 82.9 0.02 
TNFα P1-D1 -0.8 1.1 0.17 
 D1-D7 -0.2 1.4 0.72 
 P1-D7 -1.0 0.8 0.05 
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Table 4.4b: Wilcoxon signed rank test for e-selectin (ng/ml) in the cemented total 
knee arthroplasty group (n=19) 
 
  P-value 
E-selectin P1-D1 0.42 
 D1-D7 0.80 
 P1-D7 0.18 
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Figure 4.6: Graph of changes in tissue plasminogen activator levels (ng/ml) over the three 
time points (mean and standard deviation) in the cemented total knee arthroplasty group 
(n=19) against the uncemented total knee arthroplasty group (n=19) 
 
Figure 4.7: Graph of changes in von Willebrand Factor (vWF) (IU/dl) over the three time 
points (mean and standard deviation) in the cemented total knee arthroplasty group (n=19) 
against the uncemented total knee arthroplasty group (n=19) 
167 
 
 
Figure 4.8: Graph of changes in soluble CD40 ligand levels (pg/ml) over the three time points 
(mean and standard deviation) in the cemented total knee arthroplasty group (n=19) against 
the uncemented total knee arthroplasty group (n=19) 
 
Figure 4.9: Graph of changes in interleukin 6 levels (pg/ml) over the three time points (mean 
and standard deviation) in the cemented total knee arthroplasty group (n=19) against the 
uncemented total knee arthroplasty group (n=19) 
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Figure 4.10: Graph of changes in tumour necrosis factor alpha levels (pg/ml) over the three 
time points (mean and standard deviation) in the cemented total knee arthroplasty group 
(n=19) against the uncemented total knee arthroplasty group (n=19) 
 
Figure 4.11: Graph of changes in e-selectin levels (ng/ml) over the three time points (median 
and interquartile ranges) in the cemented total knee arthroplasty group (n=19) against the 
uncemented total knee arthroplasty group (n=19) 
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4.4 Flow cytometry assays of cell cytokine expression 
 
The mean, standard deviations and standard error of means of the CD1442a and CD40 
flow cytometry values are summarised in table 4.5. The values are described both in 
absolute values (cell count) and in percentages. The flow results were then analysed to 
look at changes between the three time points, the results of which are summarised in 
table 4.6. 
 
The CD1442a counts showed a statistically significant fall in the first 24 hours (p=0.022), 
then rose by day 7 which is also statistically significant at day 7 and also when 
compared to the pre-operative levels (p=0.006 and 0.025 respectively) (Figure 4.12). 
These changes are also mirrored when we look at the percentage changes. The CD40 
counts on the other hand showed a significant change from pre-operative to day 1 and 
from day 1 to day 7, for the absolute values (p=0.01 and 0.04) and the percentage 
values showed a significant change from day 1 to day 7 only (p=0.027) (Figure 4.13). 
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Table 4.5a: The mean, standard deviation and standard error means of CD1442a and 
CD40, expressed as percentage values in the cemented total knee arthroplasty 
group (n=19) 
 
 Mean Standard Deviation Standard Error Mean 
CD1442a percent P1 11.0 6.0 1.5 
CD1442a percent D1 5.7 5.4 1.4 
CD1442a percent D7 16.5 12.0 3.0 
CD40 percent P1 1.7 2.4 0.6 
CD40 percent D1 0.6 0.5 0.1 
CD40 percent D7 1.9 
 
3.2 0.8 
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Table 4.5b: Median and Inter-quartile ranges (IQR) of CD1442a and CD40, expressed 
as absolute values in the cemented total knee arthroplasty group (n=19) 
 
  Percentiles 
25th 50th (Median) 75th 
CD1442a P1 285.5 1006.5 1455.5 
 D1 124.0 296.0 1100.0 
 D7 419.2 1547.0 2378.5 
CD40 P1 34.2 110.0 183.5 
 D1 12.0 52.0 78.0 
 D7 20.7 72.0 184.0 
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Table 4.6a: Mean, standard deviation and p values of CD1442a and CD40 expressed 
as percentage values in the cemented total knee arthroplasty group (n=19) 
 
  Mean Standard deviation P value 
CD1442a 
percentage 
P1-D1 5.3 6.0 <0.01 
D1-D7 -11.1 13.0 <0.01 
P1-D7 -5.6 10.3 0.04 
CD40 
percentage 
P1-D1 1.1 2.4 0.09 
D1-D7 -1.3 3.1 0.10 
P1-D7 -0.8 2.9 0.26 
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Table 4.6b: Wilcoxon signed rank test for CD1442a andCD40 absolute values in the 
cemented total knee arthroplasty group (n=19) 
 
  P-value 
CD1442a P1-D1 0.02 
 D1-D7 0.01 
 P1-D7 0.01 
CD40 P1-D1 0.01 
 D1-D7 0.04 
 P1-D7 0.74 
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Figure 4.12: Graph of changes in CD1442a counts over the three time points (median and 
interquartile ranges) in the cemented total knee arthroplasty group (n=19) against the 
uncemented total knee arthroplasty group (n=19) 
 
Figure 4.13: Graph of changes in CD40 counts over the three time points (median and 
interquartile ranges) in the cemented total knee arthroplasty group (n=19) against the 
uncemented total knee arthroplasty group (n=19) 
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4.5 Comparison of cemented versus uncemented groups 
 
The groups were compared using independent sample t-test to look for significant 
differences in the inflammatory and endothelial response with the additional use of 
cement (polymethylmethacrylate). Table 4.7 below summarises the results. 
  
There was a statistically significant difference in the platelets response between the 
cemented and uncemented groups with respect to the time period between day 1 and 
day 7 (D1-D7) (p=0.05). From the table 4.7 we see that for the period from day 1 to day 
7 there is less of a rise in the platelet levels in the cemented group. There is also a 
similar difference in the neutrophil levels which rose less in the cemented group (Figure 
4.3). There was also no statistical difference between the two groups with respect to 
the changes in the white cell count. There was no difference with regards to the 
monocytes and C-reactive protein changes between the two groups. 
 
Table 4.8 (below) is a summary of the results when we compare the tissue plasminogen 
activator (t-PA), von Willebrand factor (vWF), soluble CD40 ligand (sCD40L), interleukin 
6 (IL6), tumour necrosis factor alpha (TNFα) and e-selectin levels. 
  
None of the variables demonstrated a statistically significant difference between the 
cemented and uncemented groups. 
   
Comparing the flow cytometry counts between the two groups (Table 4.9) showed a 
significant difference in the CD1442a levels both for the absolute values and percentage 
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changes from day 1 to day 7 (D1-D7) (p=0.03 and 0.02 respectively) (Figure 4.12). There 
were also significant differences in the first 24 hours (P1-D1) when we look at the 
percentage changes (<0.01). There was no significant difference between the two 
groups for the CD40 levels. 
 
The only parameter which demonstrated a more significant change in the cemented 
group compared to that of the uncemented group was that of the CD1442a levels. This 
showed a more statistically significant change not only in the first 24 hours but also in 
the period between day 1 to day 7 (<0.01 and p=0.02 respectively).  
     
We can therefore conclude from these results that the use of bone cement does cause a 
statistically significant rise in CD1442a levels in this group of patients which occurs in 
the first 24 hours and continues to at least day 7 post-operatively. The exact relevance 
is not clear as the actual role played by CD1442a is not well understood and is thought 
to reflect the inflammatory and thrombotic processes or in fact contribute directly to 
the ongoing atherothrombogenesis (101).  
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Table 4.7: Mean difference, standard error difference and significance of blood 
parameters between the cemented total knee arthroplasty group (n=19) and 
uncemented total knee arthroplasty group (n=19) 
 
  Mean difference Standard error difference P value 
Platelets P1-D1 -24 15 0.11 
D1-D7 40 20 0.05 
P1-D7 15 25 0.55 
White Cell 
Count 
P1-D1 0.6 0.6 0.39 
D1-D7 0.6 0.7 0.93 
P1-D7 1.1 0.6 0.09 
Neutrophils P1-D1 1.3 0.6 0.48 
D1-D7 -0.4 0.7 0.54 
P1-D7 1.1 0.5 0.03 
Monocytes P1-D1 0.1 0.1 0.40 
D1-D7 -0.8 0.1 0.55 
P1-D7 0.1 0.1 0.76 
C-reactive 
protein 
P1-D1 -4 12. 0.71 
D1-D7 -15 20 0.47 
P1-D7 -19 17 0.25 
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Table 4.8a: Mean difference, standard error difference and significance of tissue 
plasminogen activator (t-PA), von Willebrand factor (vWF), soluble CD40 ligand 
(sCD40L0, interleukin 6 (IL6) and tumour necrosis factor alpha (TNFα) levels 
between the cemented total knee arthroplasty group (n=19) and uncemented total 
knee arthroplasty group (n=19) 
 
 
 
 Mean 
difference 
Standard error difference P value 
t-PA P1-D1 0.4 2.3 0.87 
D1-D7 -2.0 2.7 0.46 
P1-D7 -0.4 2.1 0.86 
vWF P1-D1 42 24. 0.09 
D1-D7 -37 21 0.09 
P1-D7 2 18 0.91 
sCD40L P1-D1 694 713 0.34 
D1-D7 -63 699 0.93 
P1-D7 664 591 0.27 
IL6 P1-D1 -23.9 47.6 0.62 
D1-D7 -4.4 61.7 0.94 
P1-D7 -28.9 24.1 0.24 
TNFα P1-D1 -0.4 0.5 0.42 
D1-D7 -0.1 0.6 0.85 
P1-D7 -0.5 0.3 0.09 
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Table 4.8b: Mann-Whitney U test for e-selectin (ng/ml) between the cemented total 
knee arthroplasty group (n=19) and uncemented total knee arthroplasty group 
(n=19) 
 
  Percentiles 
 
P-value 
25th 
 
50th (Median) 
(Median 
75th 
 
E-selectin P1-D1 -6.3 -4.3 1.5 0.84 
 D1-D7 -3.4 0.1 3.6 0.82 
 P1-D7 -9.9 -2.7 1.9 0.84 
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Table 4.9a: Mean difference, standard error difference and significance of CD1442a 
and CD40 percentage values between the cemented total knee arthroplasty group 
(n=19) and uncemented total knee arthroplasty group (n=19) 
 
  Mean difference Standard error 
difference 
P value 
CD1442a P1-D1 275 235 0.25 
D1-D7 -736 322 0.03 
P1-D7 -460 278 0.11 
CD1442a 
percentage 
P1-D1 5.1 1.7 <0.01 
D1-D7 -8.3 3.4 0.02 
P1-D7 -3.1 2.8 0.26 
CD40 P1-D1 43 59 0.46 
D1-D7 24 33 0.47 
P1-D7 67 72 0.35 
CD40 
percentage 
P1-D1 0.7 0.5 0.23 
D1-D7 -0.2 0.7 0.73 
P1-D7 0.4 0.9 0.64 
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Table 4.9b: Mann-Whitney U test for CD1442a and CD40 absolute values  between 
the cemented total knee arthroplasty group (n=19) and uncemented total knee 
arthroplasty group (n=19) 
 
  Percentiles 
 
P-value 
25th 
 
50th (Median) 
(Median 
75th 
 
CD1442a P1-D1 -719 -177 41 0.15 
 D1-D7 -112 358 1206 0.04 
 P1-D7 -286 171 720 0.07 
CD40 P1-D1 -114 -54 -4 0.93 
 D1-D7 16 64 169 0.17 
 P1-D7 -32 19 130 0.35 
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4.6 Discussion 
 
This study differs from the previous one in that bone cement (PMMA) was used to 
‘cement’ in the knee prosthesis. We see a rise in the CRP levels which is significant in 
the first 24 hours as well as at day 7 post-operatively. This is accompanied by a 
significant rise in IL-6 levels at all three time points which mirrors the response seen in 
the previous study. When we look at the changes in the t-PA and vWF levels one might 
have expected a significant rise in the first 24 hours from the surgical trauma and 
assumed exothermic trauma from the cement to the surrounding tissues and 
vasculature. But there was not a significant rise in the first 24 hours and the vWF levels 
only became significant after 24 hours from day 1 to day 7 and remained significantly 
elevated at day 7 compared to the pre-operative levels. The t-PA levels again did not 
show a significant rise in the first 24 hours and only became significant at day 7 
compared to the pre-operative levels. None of these changes were statistically 
significant between the uncemented and cemented groups. 
     
The TNFα levels were similar to the previous study in that the levels were not 
significantly elevated until at day 7. In contrast the e-selectin levels were significant at 
day 7 which may be attributed to the exothermic reaction of the bone cement and 
relevant due to e-selectin’s role in mediating leucocyte rolling and its role in conversion 
of rolling to firm adhesion but this was not statistically different to that of the 
uncemented group.  
     
The sCD40L levels reduced significantly in the first 24 hours occurring earlier than the 
group without cement which only became significantly reduced after the initial 24 
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hours. The levels in the cemented group continued to rise significantly from day 1 to 
day 7 reflecting a more acute rise in its levels possibly due to the cement used. This 
may also reflect a more acute rise in the CD154 levels. 
     
The release of CD40 from the endothelium rose significantly from day 1 to day 7 as 
opposed to only the first 24 hours in the uncemented group, reflecting a prolonged and 
gradual rise in its levels from the exothermic reaction of the bone cement. In contrast 
to the uncemented group where there was no significant rise in the CD1442a levels at 
any of the time points, the levels in the cemented group demonstrated a significant rise 
at all time points. This was the only variable which was statistically different between 
the uncemented and cemented groups. 
 
Our current understanding of the exact role of CD1442a is not clearly understood. 
Whether it reflects the inflammatory and thrombotic process or in fact directly 
contributes to the ongoing atherothrombogenesis (101). Either way it appears that the 
used of bone cement here has a significant effect on its levels albeit the relevance at 
this current time is unknown. 
 
A review of the current literature highlights that this is the only study so far to 
specifically look at the potential effect of polymethylmethacrylate on markers of 
inflammation, endothelium and coagulation. 
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CHAPTER 5 
 
Effect of local anaesthetic infiltration intra-
operatively on the activation of markers of 
inflammation, endothelium and coagulation after 
uncemented total knee arthroplasty 
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5.1 Subject characteristics 
 
There were 20 patients recruited into this study, 2 patients were excluded one due to 
wound dehiscence which required to be taken back to theatre for a wound lavage and 
secondary closure and the other patient fell during rehabilitation sustaining a humeral 
fracture. Both these patients were excluded due to the potential effects of further 
tissue trauma and the ‘second hit’ phenomenom of the humeral fracture on the stress 
response. The mean body mass index (BMI) was 30.35kg/m2, standard deviation 6.1. 
There were 7 males (mean age 62.3 years, standard deviation 12.08) and 11 females 
(mean age 67.5 years, standard deviation 8.74). A total of 10 total knee arthroplasties 
were carried out on the left and 8 on the right. None of these characteristics were 
significantly different from the patients in the uncemented total knee arthroplasty 
group in Chapter 3. 
 
 
5.2 Blood cell counts and CRP  
 
The mean values, standard deviations and standard error of means of the white cell 
count (WCC), neutrophils (Neutro), monocytes (Mono) and C-reactive protein (CRP) are 
summarised below in table 5.1. 
  
Each of these variables where compared over three time periods, from pre-operative 
values to day 1 post-operation (P1-D1), from day 1 to day 7 post-operation (D1-D7) and 
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from pre-operative to day 7 post-operation (P1-D7), the results of which are 
summarised in table 5.2. 
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Table 5.1:  Mean, standard deviations and standard error of means of white cell 
count (WCC), neutrophils (Neutro), monocytes (Mono) (all x109/L) and C-reactive 
protein (CRP) (mg/L) pre-operatively (P1) and at day 1 (D1) and day 7 (D7) post-
operatively in the uncemented total knee arthroplasty group with local anaesthetic 
infiltration (n=18) 
 
 Mean Standard Deviation Standard Error Mean 
Plat P1 276 72 17 
Plat D1 218 73 18 
Plat D7 314 115 29 
WCC P1 7.6 1.7 0.4 
WCC D1 8.5 2.2 0.5 
WCC D7 8.0 2.4 0.6 
Neutro P1 4.7 1.6 0.4 
Neutro D1 6.1 2.1 0.5 
Neutro D7 5.6 2.1 0.5 
Mono P1 0.5 0.2 0.1 
Mono D1 0.8 0.3 0.1 
Mono D7 0.6 0.2 0.1 
CRP P1 3 11. 3 
CRP D1 74 62 15 
CRP D7 73 30 7 
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Table 5.2: Paired sample t-test of WCC, Neutrophils, monocytes and CRP in the 
uncemented total knee arthroplasty group with local anaesthetic infiltration (n=18) 
 
  Mean Standard Deviation P value 
Platelets P1-D1 59 58 <0.01 
D1-D7 -94 63 <0.01 
P1-D7 -37 75 0.02 
WCC P1-D1 -0.8 1.7 0.06 
D1-D7 0.4 2.3 0.46 
P1-D7 -0.4 1.6 0.34 
Neutro P1-D1 -1.4 1.9 <0.01 
D1-D7 0.4 2.2 0.51 
P1-D7 -1.0 1.4 0.01 
Mono P1-D1 -0.3 0.2 <0.01 
D1-D7 0.2 0.3 <0.01 
P1-D7 -0.1 -0.2 0.88 
CRP P1-D1 -71 51 <0.01 
D1-D7 3 67 0.88 
P1-D7 -70 30 
 
<0.01 
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There were significant changes in the platelets at all three time points (Figure 5.1). 
There was no statistically significant change in the white cell count in any of the three 
time points, although the time point between P1 and D1 the rise just failed to reach 
significance (p=0.061) (Figure 5.2). The neutrophils had a significant rise in the first 24 
hours (p=0.008) and remained significant elevated at day 7 compared to the pre-
operative levels (Figure 5.3). The monocytes had a significant rise in the first 24, then 
fell at day 7 (p=0.006) (Figure 5.4). The majority of the rise in C-reactive protein was in 
the first 24 hours (<0.01) and was still significant when compared to the pre-operative 
levels (Figure 5.5). 
 
There was no significant difference between these patients and those in the 
uncemented group. The only parameter which differed was the platelet levels between 
day 1 and day 7 (Table 5.3 below). 
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Figure 5.1: Graph of changes in platelet count (x109/L) over the three time points (mean and 
standard deviation) in the uncemented total knee arthroplasty group with local anaesthetic 
infiltration (n=18) against the uncemented total knee arthroplasty group on its own (n=19) 
 
Figure 5.2: Graph of changes in white cell count (x109/L) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group with local 
anaesthetic infiltration (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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Figure 5.3: Graph of changes in neutrophil count (x109/L) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group with local 
anaesthetic infiltration (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
 
Figure 5.4: Graph of changes in monocyte count (x109/L) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group with local 
anaesthetic infiltration (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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Figure 5.5: Graph of changes in C-reactive protein count (mg/L) over the three time points 
(mean and standard deviation) in the uncemented total knee arthroplasty group with local 
anaesthetic infiltration (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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Table 5.3: Mean difference, standard error difference and significance of blood 
parameters between cemented and uncemented group in the uncemented total 
knee arthroplasty group with local anaesthetic infiltration (n=18) 
 
  Mean difference Standard error 
difference 
P value 
Platelets P1-D1 3 16 0.84 
D1-D7 51 24 0.04 
P1-D7 54 32 0.09 
White Cell 
Count 
P1-D1 1 0.6 0.11 
D1-D7 0.1 0.8 0.9 
P1-D7 0.9 0.7 0.19 
Neutrophils P1-D1 1.2 0.6 0.06 
D1-D7 -0.7 0.8 0.43 
P1-D7 0.5 0.6 0.38 
Monocytes P1-D1 0.2 0.1 0.12 
D1-D7 -0.1 0.1 0.41 
P1-D7 0.1 0.1 0.45 
C-reactive 
protein 
P1-D1 -5 15 0.72 
D1-D7 4 19 0.83 
P1-D7 -1 10 0.91 
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5.3 Circulating activation markers 
 
The mean, standard deviations and standard error of means of tissue plasminogen 
activator (t-PA), von Willebrand factor (vWF), soluble CD40 ligand (sCD40L), interleukin 
6 (IL6), tumour necrosis factor (TNFα) and e-selectin (median and IQRs) are summarised 
in table 5.4a & b. 
 
Each variable was then compared over the three time points from pre-operative values 
to day 1 post-operation (P1-D1), from day 1 to day 7 post-operation (D1-D7) and from 
pre-operative to day 7 post-operation (P1-D7) (Table 5.5). 
 
The increase in t-PA levels just failed to reach significance in the first 24 hours (p=0.06) 
but became significant at day 7 (p=0.01) (Figure 5.6). VWF levels were significantly 
higher at days 1 and 7 (Figure 5.7). The sCD40L levels showed a significant fall in the 
day 1 (p=0.04) rising by day 7 (p=0.07) (Figure 5.8). IL 6 levels were significantly 
elevated at day 1 and fell by day 7 (p=0.37) (Figure 5.9). E-selectin was significantly 
lower at day 1 (p=0.01) (Figure 5.10). TNFα could not be arranged in this study due to 
exhaustion of laboratory funding. Comparing these results with the uncemented group 
(Table 5.6) we see that the vWF level from day 1 to day 7 is the only parameter which 
has shown a statistically significant difference between the two groups. 
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Table 5.4a: Mean, standard deviations and standard error of means of tissue 
plasminogen activator (t-PA) (ng/ml), von Willebrand factor (vWF) (IU/dl), soluble 
CD40 ligand (sCD40L) (pg/ml), interleukin 6 (IL6) (pg/ml) and tumour necrosis 
factor (TNFα) (pg/ml) in the uncemented total knee arthroplasty group with local 
anaesthetic infiltration (n=18) 
 
 Mean Standard Deviation Standard Error Mean 
t-PA P1 11.6 4.1 1.2 
t-PA D1 13.5 4.5 1.4 
t-PA D7 16.5 6.5 2.0 
vWF P1 110 42 10 
vWF D1 152 45 11 
vWF D7 212 42 10 
sCD40L P1 6047 1998 499 
sCD40L D1 4583 1926 481 
sCD40L D7 6218 2208 570 
IL6 P1 6.1 7.0 1.7 
IL6 D1 170.8 111.4 27.0 
IL6 D7 49.0 77.0 18.7 
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Table 5.4b: Median and Inter-quartile ranges (IQR) of e-selectin (ng/ml) in the 
uncemented total knee arthroplasty group with local anaesthetic infiltration (n=18) 
 
  Percentiles 
25th 50th (Median) 75th 
E-selectin P1 24.1 33.0 42.0 
 
 D1 23.5 27.2 33.2 
 D7 23.3 27.6 32.8 
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Table 5.5a: Paired sample t-test of tissue plasminogen activator (t-PA), von 
Willebrand factor (vWF), soluble CD40 ligand (sCD40L), interleukin 6 (IL6) and  
tumour necrosis factor (TNFα) in the uncemented total knee arthroplasty group with 
local anaesthetic infiltration (n=18) 
 
  Mean Standard Deviation P value 
t-PA P1-D1 -1.9 3.0 0.06 
 D1-D7 -3.0 6.2 0.14 
 P1-D7 -4.9 5.6 0.01 
vWF P1-D1 -42 27 <0.01 
 D1-D7 -60 32 <0.01 
 P1-D7 -101 26 <0.01 
sCD40L P1-D1 1464 2644 0.04 
 D1-D7 -1614 3195 0.07 
 P1-D7 -240 2734 0.74 
IL6 P1-D1 -164.6 109.9 <0.01 
 D1-D7 121.7 112.9 <0.01 
 P1-D7 -42.9 77.9 0.37 
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Table 5.5b: Wilcoxon signed rank test for e-selectin (ng/ml) in the uncemented total 
knee arthroplasty group with local anaesthetic infiltration (n=18) 
 
  P-value 
E-selectin P1-D1 0.01 
 D1-D7 0.28 
 P1-D7 0.29 
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Figure 5.6: Graph of changes in tissue plasminogen activator level (ng/ml) over the three 
time points (mean and standard deviation) in the uncemented total knee arthroplasty group 
with local anaesthetic infiltration (n=18) against the uncemented total knee arthroplasty 
group on its own (n=19) 
 
Figure 5.7: Graph of changes in von Willebrand Factor level (IU/dl) over the three time 
points (mean and standard deviation) in the uncemented total knee arthroplasty group with 
local anaesthetic infiltration (n=18) against the uncemented total knee arthroplasty group on 
its own (n=19) 
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Figure 5.8: Graph of changes in soluble CD40 ligand levels (pg/ml) over the three time points 
(mean and standard deviation) in the uncemented total knee arthroplasty group with local 
anaesthetic infiltration (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
 
Figure 5.9: Graph of changes in interleukin 6 levels (pg/ml) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group with local 
anaesthetic infiltration (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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Figure 5.10: Graph of changes in e-selectin levels (ng/ml) over the three time points (median 
and interquartile ranges) in the uncemented total knee arthroplasty group with local 
anaesthetic infiltration (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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5.4 Flow cytometry assays of cell cytokine expression 
 
The mean, standard deviations and standard error of means of the CD1442a and CD40 
flow cytometry values are summarised in table 5.6 a & b. The values are described both 
in absolute values (cell counts) and in percentages.  
 
The flow results were then analysed to look at changes between the three time points, 
the results of which are summarised in table 5.7a & b. 
 
The CD1442a count fell significantly in the first 24 hours and rose significantly in the 
time period between day 1 and day 7 (p=0.04, <0.01) but was not significantly elevated 
at day 7 compared to the pre-operative levels (Figure 5.11). This is reflected when we 
look at percentage changes over the same time period (p=0.01 and p=0.05 respectively). 
The CD40 counts on the other hand decreased significantly in the first 24 hour period 
(P1-D1) with respect to both the absolute values and percentage changes (p=0.00 and 
0.01 respectively) (Figure 5.12) and then rose significantly to day 7 (p=0.01) 
  
The CD1442a levels fell significantly and then rose significantly at day 7 compared to 
the patients in the uncemented group (Table 5.10a &b). 
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Table 5.6a: The mean, standard deviation and standard error means of CD1442a and 
CD40, expressed as percentage values in the uncemened total knee arthroplasty 
group with local anaesthetic infiltration (n=18) 
 
 Mean Standard Deviation Standard Error Mean 
CD1442a percent P1 12.1 5.7 1.4 
CD1442a percent D1 9.1 6.9 1.7 
CD1442a percent D7 17.0 8.9 2.2 
CD40 percent P1 1.8 0.8 0.2 
CD40 percent D1 0.9 0.7 0.2 
CD40 percent D7 8.2 14.8 3.8 
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Table 5.6b: Median and Inter-quartile ranges (IQR) of CD1442a and CD40, expressed 
as absolute values in the uncemened total knee arthroplasty group with local 
anaesthetic infiltration (n=18) 
 
  Percentiles 
25th 50th (Median) 75th 
CD1442a P1 897 1232 1578 
 D1 185 758 1231 
 P1 939 1915 2508 
CD40 P1 121 168 236 
 D1 48 67 116 
 D7 132 240 362 
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Table 5.7a: Mean, standard deviation and p values of CD1442a and CD40 expressed 
as percentage values in the total knee arthroplasty group with local anaesthetic 
infiltration (n=18) 
 
  Mean Standard deviation P value 
CD1442a 
percentage 
P1-D1 3.8 8.0 0.05 
D1-D7 -7.9 11.4 0.01 
P1-D7 -4.0 9.0 0.10 
CD40 
percentage 
P1-D1 0.8 1.0 <0.01 
D1-D7 -7.4 14.4 0.06 
P1-D7 -6.9 14.9 0.10 
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Table 5.7b: Wilcoxon signed rank test for CD1442a and CD40 absolute values in the 
total knee arthroplasty group with local anaesthetic infiltration (n=18) 
 
  P-value 
CD1442a P1-D1 0.03 
 D1-D7 0.01 
 P1-D7 0.07 
CD40 P1-D1 0.01 
 D1-D7 0.03 
 P1-D7 0.01 
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Figure 5.11: Graph of changes in CD1442a counts over the three time points (median and 
interquartile ranges) in the uncemented total knee arthroplasty group with local anaesthetic 
infiltration (n=18) against the uncemented total knee arthroplasty group on its own (n=19) 
 
Figure 5.12: Graph of changes in CD40 counts over the three time points (median and 
interquartile ranges) in the uncemented total knee arthroplasty group with local anaesthetic 
infiltration (n=18) against the uncemented total knee arthroplasty group on its own (n=19) 
208 
 
5.5 Uncemented versus local anaesthetic infiltration group to assess whether the 
local anaesthetic would dampen the inflammatory and endothelial response 
 
The groups were compared to look for significant differences in the inflammatory and 
endothelial response with the additional use of local anaesthetic infiltration intra-
operatively into the joint capsule and surrounding soft tissues (40ml 0.25% Chirocaine 
with 10ml 1:100 000 adrenaline). The table below summarises the results (Table 5.8). 
    
When we compare the blood parameters we see that there is a significant difference 
between the uncemented group and the group which received the local anaesthetic 
infiltration with reference to the changes in the platelet counts from day 1 to day 7 
(p=0.04) (Figure 5.13), here the platelets levels rose less in the local anaesthetic group. 
The changes in the neutrophil counts in the first 24 hours (P1-D1) just failed to reach 
significance (p=0.06). There was no significant difference with regards to the white cell 
count and C-reactive protein. 
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Table 5.8: Mean difference, standard error difference and significance of blood 
parameters between the uncemented total knee arthroplasty group (n=19) and the 
uncemented total knee arthroplasty group with local anaethetic infiltration (n=18) 
 
  Mean 
difference 
Standard error 
difference 
Significance 
Platelets P1-D1 3 16 0.84 
D1-D7 51 24 0.04 
P1-D7 54 31 0.09 
White Cell 
Count 
P1-D1 1 0.6 0.11 
D1-D7 0.1 0.8 0.9 
P1-D7 0.9 0.7 0.19 
Neutrophils P1-D1 1.2 0.6 0.06 
D1-D7 -0.7 
 
0.8 0.43 
P1-D7 0.5 0.6 0.38 
Monocytes P1-D1 0.2 0.1 0.12 
D1-D7 -0.1 0.1 0.41 
P1-D7 0.1 0.1 0.45 
C-reactive 
protein 
P1-D1 -5 15 0.72 
D1-D7 4 19 0.83 
P1-D7 -1 10 0.91 
 
 
 
 
 
 
210 
 
 
Figure 5.13: Graph of changes in platelet count (x109/L) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group with local 
anaesthetic infiltration (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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The table below (table 5.9a & b) is a summary of the results when we compare the 
tissue plasminogen activator (t-PA), von Willebrand factor (vWF), soluble CD40 ligand 
(sCD40L0, interleukin 6 (IL-6)  and e-selectin levels. 
   
The only variable to show a significant difference was the levels of von Willebrand 
factor from day 1 to day 7 when comparing between the two groups (p=0.01) here the 
levels rose significantly less than the uncemented group (Figure 5.7) 
 
The results of the flow cytometry are outlined in table 5.11. There were significant 
differences between the two groups with regards to the CD1442a counts for both the 
absolute values and percentage changes up to day 7 (Figure 5.11). From the figure 
below we see that the CD1442a levels fall and then rise more significantly than the 
uncemented group. 
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Table 5.9a: Mean difference, standard error difference and significance of tissue 
plasminogen activator (t-PA), von Willebrand factor (vWF), soluble CD40 ligand 
(sCD40L0, interleukin 6 (IL6) and tumour necrosis factor alpha (TNFα) levels 
between the uncemented total knee arthroplasty group with local anaesthetic 
infiltration (n=18) and the uncemented total knee arthroplasty group on its own 
(n=19) 
 
 
 
 Mean 
difference 
Standard error difference P value 
t-PA P1-D1 0.9 2.0 0.65 
D1-D7 -2.2 2.6 0.40 
P1-D7 -1.3 2.1 0.54 
vWF P1-D1 35 18 0.06 
D1-D7 -51 18 0.01 
P1-D7 -19 11 0.09 
sCD40L P1-D1 966 806 0.24 
D1-D7 -135 908 0.88 
P1-D7 742 784 0.35 
IL6 P1-D1 41.5 59.8 0.49 
D1-D7 -24.4 44.0 0.58 
P1-D7 30.3 53.4 0.57 
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Table 5.9b: Mann-Whitney U test for e-selectin (ng/ml) between the uncemented 
total knee arthroplasty group with local anaesthetic infiltration (n=18) and the 
uncemented total knee arthroplasty group on its own (n=19) 
 
  Percentiles 
 
P-value 
25th 
 
50th (Median) 
(Median 
75th 
 
E-selectin P1-D1 -6.3 -4.3 1.5 0.27 
 D1-D7 -3.4 0.1 3.6 0.27 
 P1-D7 -9.9 -2.7 1.9 0.69 
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Table 5.10a: Mean difference, standard error difference and significance of 
CD1442a and CD40 percentage values between the uncemented total knee 
arthroplasty group (n=19) and the uncemented total knee arthroplasty group with 
local anaethetic infiltration (n=18)  
 
  Mean difference Standard error 
difference 
P value 
CD1442a 
percentage 
P1-D1 4.2 2.0 0.05 
D1-D7 -7.0 3.0 0.02 
P1-D7 -2.7 2.5 0.28 
CD40 
percentage 
P1-D1 0.4 0.3 0.15 
D1-D7 -4.2 4.2 0.32 
P1-D7 -3.9 4.2 0.36 
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Table 5.10b: Mann-Whitney U test for CD1442a and CD40 absolute values  between 
the uncemented total knee arthroplasty group (n=19) and the uncemented total 
knee arthroplasty group with local anaethetic infiltration (n=18)  
 
  Percentiles 
 
P-value 
25th 
 
50th (Median) 
(Median 
75th 
 
CD1442a P1-D1 -719 -177 41 0.18 
 D1-D7 -112 358 1206 0.02 
 P1-D7 -286 171 720 0.06 
CD40 P1-D1 -114 -54 -4 0.07 
 D1-D7 16 64 169 0.22 
 P1-D7 -32 19 130 0.33 
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5.6 Discussion 
 
This is the first study to look specifically at the effects of local anaesthetic infiltration 
intra-operatively on the activation of inflammatory, endothelium and coagulation 
markers.  The hypothesis of this study was that the local infiltration of local anaesthetic 
would attenuate the inflammatory response (49). 
 
The only variables which were statistically significant when compared to the 
uncemented group were the platelets, von Willebrand factor and the CD1442a. The 
platelets showed a significant difference from day 1 to day 7 whereas the von 
Willebrand factor was significant from pre-operative levels to day 1 and from day 1 to 
day 7. This difference may in part be due to the possible further local surgical trauma 
from the infiltration of the relatively large volume of local anaesthetic into the peri-
operative field. But as we will see in Chapter 7 these changes in the platelets and von 
Willebrand factor are not significant in the context of all the four groups together.  
     
In the anaesthetic group we again see a significant change in the CD1442a levels both 
over the first 24 hours and from day 1 to day 7 which is not reflected in the uncemented 
group. This is similar to the result we see when we compared the uncemented and 
cemented group. The significance as noted before is unclear, whether this reflects the 
thrombotic and inflammatory process or the process of atherothrombogenesis. It may 
reflect the thrombotic process as we see a significant difference in the vWF levels in 
the local anaesthetic group not seen in the uncemented group. One possible reason is 
that in the first 24 hours the levels may have been reduced by the use of local 
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anaesthetic to a level so that as their levels rose back up again it became significant. 
There is no difference as regards the changes in the CD40 level changes. 
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CHAPTER 6 
 
The effect of using of a drain post-operatively on 
the activation of markers of inflammation, 
endothelium and coagulation after uncemented 
total knee arthroplasty 
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6. Results 
 
There were 20 patients recruited into this study, 2 patients were excluded from the 
study due to superficial wound infections, leaving 18 patients. Both of the excluded 
patients had positive wound cultures. One was successfully treated with antibiotics but 
the other patient required a secondary procedure in the form of a wound wash-out. 
These patients were excluded due to possible effects of the wound infection and wound 
wash-out would have on the inflammatory response. The mean body mass index (BMI) 
was 28.37kg/m2 with a standard deviation of 6.1. There were 6 males (mean age 70.3 
years, standard deviation 3.98) and 12 females (mean age 64 years, standard deviation 
10.32). A total of 6 total knee arthroplasties were carried out on the left and 12 on the 
right. None of these characteristics was significantly different from the patients in the 
uncemented group in Chapter 3. 
 
 
6.1 Blood cell counts and CRP 
 
The mean values, standard deviation and standard error of means of the white cell 
count (WCC), neutrophils (Neutro), monocytes (Mono) and C-reactive protein (CRP) are 
summarised below in table 6.1. Each of those variables were compared over three time 
periods, from pre-operative values to day 1 post-operation (P1-D1), from day 1 to day 7 
post-operation (D1-D7) and from pre-operative to day 7 post-operation (P1-D7), the 
results of which are summarised in table 6.2. 
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The platelet count fell then rose significantly (Figure 6.1). The white cell count rose 
then fell significantly (Figure 6.2) but the neutrophils did not show a significant change 
(Figure 6.3). The monocytes showed a significant rise in the first 24 hours and were still 
significantly higher than the pre-operative levels at day 7 (p=0.00) (Figure 6.4). C-
reactive protein levels (Figure 6.5), which were significantly higher at day 1 and 7. 
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Table 6.1:  Mean, standard deviation and standard error of means of white cell 
count (WCC), neutrophils (Neutro), monocytes (Mono) (all x109/L) and C-reactive 
protein (CRP) (mg/L) at pre-operative (P1), day 1 (D1) and day 7 (D7) post-
operatively in the uncemented total knee arthroplasty group with a post-operative 
surgical drain (n=18) 
 
 Mean Standard Deviation Standard Error Mean 
Plat P1 241 32 8 
Plat D1 210 61 14 
Plat D7 299 109 26 
WCC P1 248.4 70.4 17 
WCC D1 196.4 46.4 11.3 
WCC D7 309.6 60.3 14.6 
Neutro P1 7.2 1.4 0.4 
Neutro D1 8.1 2.1 0.5 
Neutro D7 7.7 1.8 0.4 
Mono P1 0.5 0.1 0.1 
Mono D1 0.8 0.3 0.1 
Mono D7 0.6 0.2 0.1 
CRP P1 1 3 0.8 
CRP D1 69 36 9 
CRP D7 69 40 10 
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Table 6.2: Paired sample t-tests of WCC, neutrophils, monocytes and CRP in the 
uncemented total knee arthroplasty group with a post-operative surgical drain 
(n=18) 
 
  Mean Standard Deviation P value 
Plat P1-D1 31 54 0.02 
D1-D7 89 70 <0.01 
P1-D7 58 97 0.02 
WCC P1-D1 52.0 34.6 <0.01 
D1-D7 -113.2 49.2 <0.01 
P1-D7 -61.2 57.7 <0.01 
Neutro P1-D1 -0.9 2.1 0.09 
D1-D7 0.5 2.3 0.42 
P1-D7 -0.4 1.4 0.23 
Mono P1-D1 -1.6 2.1 0.01 
D1-D7 0.6 1.9 0.24 
P1-D7 -1.0 1.3 0.01 
CRP P1-D1 -68 37 <0.01 
D1-D7 0.1 61 0.99 
P1-D7 -68 40 <0.01 
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Figure 6.1: Graph of changes in platelet count (x109/L) over the three time points (mean and 
standard deviation) in the uncemented total knee arthroplasty group with a post-operative 
surgical drain (n=18) against the uncemented total knee arthroplasty group on its own (n=19) 
 
Figure 6.2: Graph of changes in white cell count (x109/L) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group with a post-
operative surgical drain (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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Figure 6.3: Graph of changes in neutrophils count (x109/L) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group with a post-
operative surgical drain (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
 
Figure 6.4: Graph of changes in monocyte count (x109/L) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group with a post-
operative surgical drain (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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Figure 6.5: Graph of changes in C-reactive protein (mg/l) level over the three time points 
(mean and standard deviation) in the uncemented total knee arthroplasty group with a post-
operative surgical drain (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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6.3 Circulating activation markers 
  
The mean, standard deviations and standard error of means of tissue plasminogen 
activator (t-PA), von Willebrand factor (vWF), soluble CD40 ligand (sCD40L), interleukin 
6 (IL-6), tumour necrosis factor (TNFα) and e-selectin are summarised in table 6.3a & b. 
 
Each variable was then compared over the three time points from pre-operative values 
to day 1 post-operation (P1-D1), from day 1 to day 7 post-operation (D1-D7) and from 
pre-operative to day 7 post-operation (P1-D7) (Table 6.4a & b). 
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Table 6.3a: Mean, standard deviations and standard error of means of tissue 
plasminogen activator (t-PA) (ng/ml), von Willebrand factor (vWF) (IU/dl), soluble 
CD40 ligand (sCD40L) (pg/ml), interleukin 6 (IL6) (pg/ml) and  tumour necrosis factor 
(TNFα) (pg/ml)  in the uncemented total knee arthroplasty group with a post-
operative surgical drain (n=18)  
 
 Mean Standard Deviation Standard Error Mean 
t-PA P1 13.1 3.6 0.9 
t-PA D1 13.5 4.4 1.2 
t-PA D7 17.3 7.7 2.0 
vWF P1 125 47 12 
vWF D1 192 81 21 
vWF D7 222 64 17 
sCD40L P1 5233 2383 615 
sCD40L D1 3605 2106 544 
sCD40L D7 6000 2711 699 
IL6 P1 3.9 2.0 0.5 
IL6 D1 137.8 88.5 22.8 
IL6 D7 42.9 84.4 21.8 
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Table 6.3b: Median and Inter-quartile ranges (IQR) of e-selectin (ng/ml) in the 
uncemented total knee arthroplasty group with a post-operative surgical drain 
(n=18)  
 
  Percentiles 
25th 50th (Median) 75th 
E-selectin P1 21.3 24.9 39.1 
 D1 17.0 25.9 31.2 
 D7 20.7 25.8 32.9 
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Table 6.4a: Paired sample t-test of tissue plasminogen activator (t-PA) (nG/ML), von 
Willebrand factor (vWF) (IU/dl), soluble CD40 ligand (sCD40L) (pg/ml), interleukin 6 
(IL6) (pg/ml)and tumour necrosis factor (TNFα) (pg/ml) in the uncemented total knee 
arthroplasty group with a post-operative surgical drain (n=18)  
 
  Mean Standard Deviation P value 
t-PA P1-D1 -0.4 4.3 0.75 
 D1-D7 -3.8 6.3 0.04 
 P1-D7 -4.2 7.0 0.04 
vWF P1-D1 -67 67 <0.01 
 D1-D7 -29 79 0.17 
 P1-D7 -97 38 <0.01 
sCD40L P1-D1 1628 1490 <0.01 
 D1-D7 -2395 2518 <0.01 
 P1-D7 -766 2272 0.21 
IL6 P1-D1 -133.9 88.2 <0.01 
 D1-D7 94.8 86.9 0.01 
 P1-D7 -39.0 88.1 0.09 
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Table 6.4b: Wilcoxon signed rank test for e-selectin (ng/ml) in the uncemented total 
knee arthroplasty group with a post-operative surgical drain (n=18)  
 
  P-value 
E-selectin P1-D1 0.06 
 D1-D7 0.30 
 P1-D7 0.92 
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The t-PA levels showed a rise which was maintained to day 7 (p=0.04) (Figure 6.6). The 
vWF was significant at 24 hours and remained so at day 7 when compared to the pre-
operative levels (p=0.00) (Figure 6.7). The levels of sCD40L fell significantly in the first 
24 hours and rose from day 1 to day 7 (p=0.00) (Figure 6.8). IL6 levels rose significantly 
to day 7 (p=0.00) (Figure 6.9). E-selectin did not change significantly (Figure 6.10). 
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Figure 6.6: Graph of changes in tissue plasminogen activator level (ng/ml) over the three 
time points (mean and standard deviation) in the uncemented total knee arthroplasty group 
with a post-operative surgical drain (n=18) against the uncemented total knee arthroplasty 
group on its own (n=19) 
 
Figure 6.7: Graph of changes in von Willebrand Factor level (IU/dl) over the three time 
points (mean and standard deviation) in the uncemented total knee arthroplasty group with 
a post-operative surgical drain (n=18) against the uncemented total knee arthroplasty group 
on its own (n=19) 
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Figure 6.8: Graph of changes in soluble CD40 ligand level (pg/ml) over the three time points 
(mean and standard deviation) in the uncemented total knee arthroplasty group with a post-
operative surgical drain (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
 
Figure 6.9: Graph of changes in interleukin 6 level (pg/ml) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group with a post-
operative surgical drain (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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Figure 6.10: Graph of changes in e-selectin level (ng/ml) over the three time points (median 
and interquartile ranges) in the uncemented total knee arthroplasty group with a post-
operative surgical drain (n=18) against the uncemented total knee arthroplasty group on its 
own (n=19) 
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6.4 Flow cytometry assays of cell cytokine expression 
 
The mean, standard deviation and standard error of mean of the CD1442a and CD40 
levels are summarised in table 6.6a & b for both absolute (cell counts) and percentage 
values. 
 
The flow results were then analysed to look at changes between the three time points, 
the results of which are summarised in table 6.7a & b. 
 
There were no significant changes in the CD1442a counts at any of the three time points 
for either the absolute or percentage levels (Figure 6.11). The CD40 counts fell 
significantly in the first 24 hours (P1 to D1) only (p=0.009) (Figure 6.12). 
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Table 6.5a: The mean, standard deviation and standard error means of CD1442a and 
CD40, expressed as percentage values in the uncemented total knee arthroplasty 
group with surgical drain (n=18) 
 
 Mean Standard Deviation Standard Error Mean 
CD1442a percent P1 10.00 6.13 1.53 
CD1442a percent D1 8.16 5.33 1.33 
CD1442a percent D7 11.44 8.86 2.21 
CD40 percent P1 1.43 1.20 0.29 
CD40 percent D1 0.88 0.73 0.18 
CD40 percent D7 1.43 0.83 0.20 
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Table 6.5b: Median and Inter-quartile ranges (IQR) of CD1442a and CD40, expressed 
as absolute values in the uncemented total knee arthroplasty group with surgical 
drain (n=18) 
 
  Percentiles 
25th 50th (Median) 75th 
CD1442a P1 527 1262 1533 
 D1 181 1022 1188 
 D7 399 1118 2154 
CD40 P1 62 122 186 
 D1 42 58 131 
 D7 73 129 303 
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Table 6.6a: Mean, standard deviation and p values of CD1442a and CD40 expressed 
as percentage values in the uncemented total knee arthroplasty group with surgical 
drain (n=18) 
 
  Mean Standard deviation P value 
CD1442a 
percentage 
P1-D1 1.8 5.2 0.18 
D1-D7 -3.3 7.4 0.09 
P1-D7 -1.4 6.3 0.37 
CD40 
percentage 
P1-D1 0.5 0.8 0.01 
D1-D7 -0.5 0.7 >0.01 
P1-D7 -0.01 0.9 0.99 
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Table 6.6b: Wilcoxon signed rank test for CD1442a andCD40 absolute values in the 
uncemented total knee arthroplasty group with surgical drain (n=18) 
 
  P-value 
CD1442a P1-D1 0.05 
 D1-D7 0.20 
 P1-D7 0.27 
CD40 P1-D1 0.01 
 D1-D7 <0.01 
 P1-D7 0.18 
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Figure 6.11: Graph of changes in CD1442a counts over the three time points (median and 
interquartile ranges) in the uncemented total knee arthroplasty group with surgical drain 
(n=18) against the uncemented total knee arthroplasty group on its own (n=19) 
 
Figure 6.12: Graph of changes in CD40 counts over the three time points (median and 
interquartile ranges) in the uncemented total knee arthroplasty group with surgical drain 
(n=18) against the uncemented total knee arthroplasty group on its own (n=19) 
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6.5 Uncemented group versus the group with a surgical drain to assess any effect 
this would have on the inflammatory and endothelial response. 
 
The groups were compared using independent sample t-test to look for significant 
differences in the inflammatory and endothelial response with the additional use of a 
surgical drain post-operatively for 24 hours. 
   
The table below summarises the results of the independent sample t-tests for the blood 
parameters (table 6.9). 
 
The only blood parameter which was significantly different between the two groups was 
the change in monocyte counts in the first 24 hours (p=0.04) (Figure 6.13). Here the 
monocytes rose less significantly then the uncemented group. 
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Table 6.7: Mean difference, standard error difference and significance of blood 
parameters between uncemented total knee arthroplasty group with surgical drain 
(n=18) and the uncemented total knee arthroplasty group on its own (n=19). 
 
  Mean difference Standard error 
difference 
P value 
Platelets P1-D1 -4 13 0.76 
D1-D7 16 17 0.36 
P1-D7 34 28 0.23 
White Cell 
Count 
P1-D1 1.5 0.9 0.08 
D1-D7 -0.6 0.7 0.43 
P1-D7 1.0 0.7 0.18 
Neutrophils P1-D1 1.4 0.8 0.07 
D1-D7 -0.9 0.7 0.19 
P1-D7 0.5 0.6 0.41 
Monocytes P1-D1 0.2 0.1 0.04 
D1-D7 -0.1 0.1 0.25 
P1-D7 0.1 0.1 0.29 
C-reactive 
protein 
P1-D1 1 13 0.91 
D1-D7 -0.4 18 0.98 
P1-D7 1 12 0.93 
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Figure 6.13: Graph of changes in monocyte count (x109/L) over the three time points (mean 
and standard deviation) in the uncemented total knee arthroplasty group with surgical drain 
(n=18) against the uncemented total knee arthroplasty group on its own (n=19) 
 
 
 
 
 
 
 
 
 
 
244 
 
 The table below (Table 6.8a & b) is a summary of the results when we compare the 
tissue plasminogen activator (t-PA), von Willebrand factor (vWF), soluble CD40 ligand 
(sCD40L), interleukin 6 (IL-6), tumour necrosis factor alpha (TNFα) and e-selectin levels 
between the two groups. There does not appear to have been a statistically significant 
difference with the additional usage of a post-operative drain. 
  
In terms of the flow cytometry results (Table 6.9a & b) there were no significant 
difference between the uncemented group and the group with the additional use of a 
surgical drain. The changes in the drain group did not show a statistically significant 
difference with regards to the CRP levels, although the IL-6 levels in this group were 
only significantly elevated from day 1 to day 7 the changes in their levels were not 
significantly different to that of the uncemented group.  
  
There was no difference in the t-PA, vWF and e-selectin levels. The sCD40L showed a 
significant change in the first 24 hours and from day1 to day 7, similar to that of the 
cemented group. But when we look at the difference in the levels between the three 
time point we se that there is no difference between the drain and uncemented group. 
There was also no difference in the change in the CD1442a and CD40 levels. 
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Table 6.8a: Mean difference, standard error difference and significance of tissue 
plasminogen activator (t-PA), von Willebrand factor (vWF), soluble CD40 ligand 
(sCD40L0, interleukin 6 (IL-6) and tumour necrosis factor alpha (TNFα) levels 
between the uncemented total knee arthroplasty group with surgical drain (n=18) 
and the uncemented total knee arthroplasty group on its own (n=19) 
 
  Mean 
difference 
Standard error difference P value 
t-PA P1-D1 2.5 1.9 0.21 
D1-D7 -3.0 2.4 0.22 
P1-D7 -0.6 2.2 0.79 
vWF P1-D1 9 25 0.70 
D1-D7 -21 26 0.44 
P1-D7 -15 13 0.27 
sCD40L P1-D1 1131 635 0.08 
D1-D7 -915 782 0.25 
P1-D7 216 698 0.76 
IL6 P1-D1 23 36 0.52 
D1-D7 -51 42 0.23 
P1-D7 -13 24 0.59 
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Table 6.8b: Mann-Whitney U test for e-selectin (ng/ml) between the uncemented 
total knee arthroplasty group with surgical drain (n=18) and the uncemented total 
knee arthroplasty group on its own (n=19) 
 
  Percentiles 
 
P-value 
25th 
 
50th (Median) 
(Median 
75th 
 
E-selectin P1-D1 -6.3 -4.3 1.5 0.52 
 D1-D7 -3.4 0.1 3.6 0.56 
 P1-D7 -9.9 -2.7 1.9 0.29 
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 Table 6.9a: Mean difference, standard error difference and significance of CD1442a 
and CD40 percentage values between the uncemented total knee arthroplasty group 
with surgical drain (n=18) and the uncemented total knee arthroplasty group on its 
own (n=19). 
 
  Mean difference Standard error 
difference 
P value 
CD1442a 
percentage 
P1-D1 2.2 1.5 0.16 
D1-D7 -2.4 2.2 0.28 
P1-D7 -0.2 2.0 0.93 
CD40 
percentage 
P1-D1 0.2 0.2 0.48 
D1-D7 -6.1 3.4 0.07 
P1-D7 -5.9 3.3 0.09 
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Table 6.9b: Mann-Whitney U test for CD1442a and CD40 absolute values  between 
the uncemented total knee arthroplasty group with surgical drain (n=18) and the 
uncemented total knee arthroplasty group on its own (n=19). 
 
  Percentiles 
 
P-value 
25th 
 
50th (Median) 
(Median 
75th 
 
CD1442a P1-D1 -719 -177 41 0.45 
 D1-D7 -112 358 1206 0.05 
 P1-D7 -286 171 720 0.35 
CD40 P1-D1 -114 -54 -4 0.80 
 D1-D7 16 64 169 0.90 
 P1-D7 -32 19 130 0.82 
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6.6 Discussion 
 
This is the first study to specifically look at the effect of the use of a post-operative 
drain on the activation of markers of inflammation, endothelium and coagulation in TKA 
patients. The hypothesis of this study was that the use of a surgical drain would allow 
for the local inflammatory mediators such as IL-6 and TNFα to drain away from the 
operative site and so attenuate the local inflammatory response (215) 
 
In this group this use of a drain post-operatively did not affect the CRP response which 
was similar to that of the uncemented group. However the IL6 response was different in 
that there was no significant rise in the first 24 hours and rose significantly from day 1 
to day 7, even then the levels reached were not significantly higher that those of the 
pre-operative levels. Therefore there is some suggestion that the use of a drain may 
somehow dampen the local IL-6 response although this was not statistically different to 
the uncemented group or all four groups combined (Chapter 7). 
   
Both the CD1442a and CD40 levels show similar changes but was not statistically 
different when compared to the uncemented group. 
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CHAPTER 7 
Comparison of the four study groups and 
collaboration of the results 
 
 
 
 
 
 
 
 
 
251 
 
7.1 Introduction 
 
During the data collection and following analysis of the variables in the previous 
chapters we can see that although there were significant changes following total knee 
arthroplasty there was no significance when the groups were compared, except for the 
flow cytometry comparison with the cemented group. 
 
This aim of this chapter was to formally compare the changes in those variables across 
all four groups. These will then be collated to present the effects of total knee 
arthroplasty on the activation of markers of endothelium, inflammation and coagulation 
in 76 patients, which will be the single largest study to date to report these findings. 
 
 
7.2 Statistical analysis 
 
For the parametric data repeated measures ANOVA was used to look for statistical 
difference in the variables between groups. A p value of less than or equal to 0.05 was 
considered to be significant. The group was analysed as a whole, utilising repeated 
measures ANOVA with group (cemented, uncemented, local anaesthetic and drain) as a 
between subjects factor and time as a within subjects factor. Age, sex and BMI were 
covariates. A Bonferroni correction for multiple comparisons was performed.  
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In the case of the non-parametric data (e-selectin, CD1442a and CD40 count) the 
Freidmans test was used with post hoc Wilcoxon Signed Rank test to look for  
differences between the groups with a p-value of less then 0.017 (0.05 divived by the 3) 
as being significant. All analyses were performed using SPSS version 19.0 for Windows 
(SPSS Inc., Chicago, IL, USA). 
 
 
7.3 Results 
 
The table below (Table 7.1a & b) shows the results of all the variables with their p-
values. The only variable which showed a statistical difference between the groups 
(cemented versus uncemented) was in the CD1442a percentage change which confirms 
the conclusions drawn from previous chapters. 
 
Although there was perceived significance for the time period for CD40 from day 1 to 
day 7 (p=0.01), post-hoc Wilcoxon Signed-Rank test was conducted with a Bonferroni 
correction applied, giving a significance level of p<0.017. Analysis of the day 1 to day 7 
timepoint for CD40 gave p values of 0.44 (uncemented versus cemented group); 0.06 
(uncemented versus local anaesthetic group); 0.39 (uncemented versus local drain 
group) therefore showing this not to be significant. 
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Table 7.1a: Results of repeated measures ANOVA with p-values in all four total knee 
arthroplasty groups except e-selectin and CD40 count (n=74) 
 
Variables P value 
Platelets 0.31 
White cell count 0.62 
Neutrophils 0.24 
Monocytes 0.29 
CRP 0.74 
TPA 0.93 
vWF 0.14 
Soluble CD40L 0.75 
IL6 0.99 
TNF 0.84 
CD1442a % <0.01 
CD40 %  0.49 
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Table 7.1b: Results of Freidman test on CD40 and e-selectin (ng/ml) count for all 
three time points in four total knee arthroplasty groups (n=74) 
 
  P-value 
CD1442a P1-D1 0.43 
 D1-D7 0.10 
 P1-D7 0.31 
CD40 P1-D1 0.31 
 D1-D7 0.01 
 P1-D7 0.19 
e-selectin P1-D1 0.98 
 D1-D7 0.87 
 P1-D7 0.77 
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The data was then combined (excluding the data on CD1442a) and analysed to report 
the changes between each of the three time points for the 76 patients (the only 
exception was in the analysis of TNFα in only 40 patients). The mean, standard 
deviation and standard error of mean are shown below in table 7.2a and the median and 
IQRs for CD40 and e-selectin count in table 7.2b. 
 
Table 7.3a & b demonstrates that all variables show a significant changes at all three 
time point apart from e-selectin and C-reactive protein at the day 1 to day 7 time 
period and interleukin 6 for the pre-operative to day 7 time period, reflecting and 
confirming the results of the previous chapters. Graphs 7.1 to 7.12 are graphical 
representations of the changes in table 7.3. 
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Table 7.2a: Mean, standard deviation and standard error of mean of platelets, white 
cell count (WCC), neutrophils, monocytes (all 109/L), C-reactive protein (mg/L), 
tissue plasminogen activator (t-PA) (ng/ml), von Willebrand factor (vWF) (IU/dl), 
soluble CD40L (pg/ml), interleukin 6 (IL6) (pg/ml) and CD40 percentage values 
excluding CD1442 in all four total knee arthroplasty groups (n=74) 
 
 Mean Standard deviation Standard error of 
mean 
Plat P1 256 63 8 
Plat D1 207 59 7 
Plat D7 314 92 11 
WCC P1 7.6 1.5 0.2 
WCC D1 8.9 2.3 0.3 
WCC D7 8.1 2.1 0.2 
Neutro P1 4.7 1.4 0.2 
Neutro D1 6.4 2.1 0.2 
Neutro D7 5.5 1.7 0.2 
Mono P1 0.6 0.2 0.02 
Mono D1 0.9 0.4 0.05 
Mono D7 0.7 0.2 0.03 
CRP P1 2 6 0.7 
CRP D1 70 43 5 
CRP D7 74 44 5 
t-PA P1 12.1 3.8 0.5 
t-PA D1 14.0 5.2 0.7 
t-PA D7 16.4 7.0 0.9 
vWF P1 126 52 7 
vWF D1 181 68 8 
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vWF D7 217 53 7 
sCD40L P1 4667 2435 307 
sCD40L D1 3501 2219 279 
sCD40L D7 5229 2481 315 
IL6 P1 28.5 134.9 16.7 
IL6 D1 168.1 119.2 14.8 
IL6 D7 46.4 73.1 9.2 
CD40 P1 percent 1.6 1.5 0.2 
CD40 D1 percent 0.8 0.7 0.1 
CD40 D7 percent 5.0 11.0 1.4 
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Table 7.2b: Median and Inter-quartile ranges (IQR) of e-selectin (ng/ml) and CD40 
count in all four total knee arthroplasty groups (n=74) 
 
  Percentiles 
25th 50th (Median) 75th 
E-selectin P1 -6.3 -4.3 1.5 
 D1 -3.4 0.1 3.6 
 D7 -9.9 -2.7 1.9 
CD40 P1 -112.5 -49.0 -4.0 
 D1 16.0 66.0 174.0 
 D7 -18.0 24.0 139.0 
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Table 7.3a: Mean difference, standard error difference and significance of platelets, 
white cell count, neutrophils, monocytes, C-reactive protein, tissue plasminogen 
activator (t-PA), von Willebrand Factor (vWF), soluble CD40 ligand and CD40 
percentage values in all four total knee arthroplasty groups (n=74) 
  Mean Standard deviation P value 
Platelets P1-D1 49 46 <0.01 
D1-D7 -107 60 <0.01 
P1-D7 -58 80 <0.01 
White Cell 
Count 
P1-D1 -1.2 1.9 <0.01 
D1-D7 0.8 2.2 <0.01 
P1-D7 -0.5 1.5 0.01 
Neutrophils P1-D1 -1.7 2.0 <0.01 
D1-D7 0.9 2.2 <0.01 
P1-D7 -0.9 1.4 <0.01 
Monocytes P1-D1 -0.4 0.3 <0.01 
D1-D7 0.3 0.4 <0.01 
P1-D7 -0.1 0.3 <0.01 
C-reactive 
protein 
P1-D1 -68 40 <0.01 
D1-D7 -3 62 0.70 
P1-D7 -72 44 <0.01 
t-PA P1-D1 -1.9 5.0 0.01 
D1-D7 -2.4 6.6 0.01 
P1-D7 -4.1 5.7 <0.01 
vWF P1-D1 -55 61 <0.01 
D1-D7 -69 61 <0.01 
P1-D7 -90 44 <0.01 
sCD40L P1-D1 1166 2082 <0.01 
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D1-D7 -1745 2423 <0.01 
P1-D7 -601 2087 0.02 
IL6 P1-D1 -139.6 184.0 <0.01 
D1-D7 126.6 140.8 <0.01 
P1-D7 -16.9 158.4 0.40 
CD40 
percentage 
P1-D1 0.8 1.4 <0.01 
D1-D7 -4.3 10.8 <0.01 
P1-D7 -3.7 10.7 0.01 
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Table 7.4b: Wilcoxon signed rank test for eselectin and CD40 absolute values in all 
four total knee arthroplasty groups (n=74) 
 
  P-value 
e-selectin P1-D1 0.03 
 D1-D7 <0.01 
 P1-D7 0.99 
CD40 P1-D1 <0.01 
 D1-D7 <0.01 
 P1-D7 <0.01 
 
 
 
 
 
 
 
 
 
 
 
 
262 
 
 
Figure 7.1: Graph of changes in platelet counts over the three time points (mean and 
standard deviation) in all four total knee arthroplasty groups (n=74) 
 
 
Figure 7.2: Graph of changes in white cell counts over the three time points (mean and 
standard deviation) in all four total knee arthroplasty groups (n=74) 
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Figure 7.3: Graph of changes in neutrophil counts over the three time points (mean and 
standard deviation) in all four total knee arthroplasty groups (n=74) 
 
 
Figure 7.4: Graph of changes in monocyte counts over the three time points (mean and 
standard deviation) in all four total knee arthroplasty groups (n=74) 
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Figure 7.5: Graph of changes in C-reactive protein levels over the three time points (mean 
and standard deviation) in all four total knee arthroplasty groups (n=74) 
 
 
Figure 7.6: Graph of changes in tissue plasminogen activator levels over the three time 
points (mean and standard deviation) in all four total knee arthroplasty groups (n=74) 
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Figure 7.7: Graph of changes in von Willebrand factor levels over the three time points 
(mean and standard deviation) in all four total knee arthroplasty groups (n=74) 
 
 
Figure 7.8: Graph of changes in soluble CD40L levels over the three time points (mean and 
standard deviation) in all four total knee arthroplasty groups (n=74) 
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Figure 7.9: Graph of changes in interleukin 6 levels over the three time points (mean and 
standard deviation) in all four total knee arthroplasty groups (n=74) 
 
 
Figure 7.10: Graph of changes in e-selectin levels over the three time points (median and 
interquartile ranges) in all four total knee arthroplasty groups (n=74) 
 
267 
 
 
 
 
 
 
 
 
Figure 7.11: Graph of changes in CD40 levels over the three time points (median and 
interquartile ranges) in all four total knee arthroplasty groups (n=74) 
 
 
Figure 7.12: Graph of changes in CD40 percentage over the three time points (mean and 
standard deviation) in all four total knee arthroplasty groups (n=74) 
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7.4 Discussion 
This is the single largest study to date looking at the effects of total knee arthroplasty 
(n=74) on the markers of inflammation, coagulation and of endothelial function. As part 
of the ‘surgical response’ to surgery we see a significant fall then rise with regards to 
the platelet levels due to the activation of the coagulation pathways (p<0.01) (figure 
7.1). This is also reflected by the significant falls in the levels of both the vWF and t-PA 
at all three time points (p<0.01) (figure 7.6 & 7.7). 
 
The white cell count, monocyte and neutrophils levels all showed a significant rise from 
the pre-operative levels to day 1 and fell significantly from day 1 to day 7 (p<0.01). 
Even at day 7 the levels of the white cell count, monocyte and neutrophils still 
remained significantly elevated compared to the pre-operative levels reflecting the 
continued surgical stimulus (p<0.01). The C-reactive protein levels rose significantly in 
the first 24 hours following surgery (p<0.01) as part of the acute phase response and 
although the levels continued to rise there was not a significant rise from day 1 to day 7 
(p=0.70).  But the levels at day 7 still remained significantly elevated compared to the 
pre-operative levels. By comparison the IL6 although were significantly elevated in the 
first 24 hours and continued to significantly rise to day 7 (p<0.01) were not significantly 
elevated at day 7 when compared to the pre-operative levels (p=0.40). 
 
The sCD40L showed a signficant fall in the first 24 hours (p<0.01) followed by a 
significant rise from day 1 to day 7 (p<0.01) but remained significantly low at day 7 
compared to the pre-operative levels. The levels of sCD40L has been shown to reflect 
plaque stability and composition (80). The CD40 levels expressed from the endothelium 
of inflamed tissues (84) was significantly elevated in the first 24 hours and continues to 
do so to day 7 (p<0.01). At day 7 it remains significantly elevated compared to the pre-
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operative levels (p=0.01). CD40 has been shown to be involved in a variety of functions 
from immunity to inflammation (84). 
 
This study demonstrates that elective total knee arthroplasty results in significant 
changes in the markers of inflammation, coagulation and of endothelial function. 
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CHAPTER 8 
 
Discussion and Future Research 
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8.1 Discussion 
 
There is very little in the current literature which investigates the effect of total knee 
replacement on the markers of inflammation, endothelium and coagulation. The aim of 
the studies undertaken in this thesis were to investigate such a potential association. 
Although the instrumentation to undertake the knee replacement is generally 
standardised there are variations which exits. Traditionally ‘bone cement’ would be 
used to ‘cement in’ the prosthesis but an option now exists to implant these 
uncemented. Some surgeons regularly use a post-operative surgical drain for 24-48 
hours and with the current drive to increase efficiency and workload through the 
National Health Service, local anaesthetic infiltration has been used intra-operatively to 
improve post-operative pain control and patient mobilisation to allow for early 
discharge. The other three studies in this thesis specifically examines the use of bone 
cement, surgical drain and local anaesthetic and the effect on the markers of 
inflammation, endothelium and coagulation. 
 
In chapter 4 the cemented and uncemented groups were directly compare to one 
another. The only parameter which showed a significant difference between the groups 
was the CD1442a levels. The levels were significantly different in the first 24 hours 
(p<0.01) and from day 1 to day 7 post-operatvely. The exact role of CD1442a is not 
known, so the difference between these two groups with respect to the CD1442a levels 
may reflect the impact that the cement has on the inflammatory and thrombotic 
process or on its contribution to the ongoing atherothrombogenesis.  A comparison 
between the uncemented and local anaesthetic group (Chapter 5) revealed that both 
the platelet and von Willebrand factor levels rose less significantly from day 1 to day 7. 
There was no difference in the IL-6 levels between the groups which does not support 
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the in vitro studies which demonstrate that local anaesthetic results in attenuation of 
the inflammatory response (49). When a comparison was made to the surgical drain 
group the monocytes rose less from pre-operative levels to day 1 (p=0.04). The IL-6 
levels compared to the uncemented group also showed a significant difference. Here 
there was no significant rise in the first 24 hours as was seen in the uncemented group 
and although the levels rose thereafter the day 7 levels were not significant compared 
to the pre-operative levels. This would possibly support the hypothesis that the use of 
the surgical drain allows the local IL-6 accumulation to drain away (215) and so 
contribute less to the systemic response. The only variable which showed a statistically 
significant difference in all three of the comparison groups was the CD1442a count. The 
exact role of CD1442a is not clearly understood, whether it reflects the inflammatory 
and thrombotic process or in fact directly contributes to the ongoing 
atherothrombogenesis (103). This would fit well with the hypothesis that the 
exothermic reaction of the bone cement in the cemented group would have caused 
additional inflammatory and thrombotic response. Unfortunately there is no current 
literature to support or refute this. 
 
It was during the writing up of the results in the previous chapters when it was noted 
that it seemed that the majority of the variables demonstrated similar changes 
throughout all the four study groups. In chapter 7 an ANOVA and Friedman analysis was 
undertaken which showed that in fact all but one of the variables, the CD1442a count, 
showed no statistical difference between all the groups. These variables were then 
combined to present the single largest cohort to date investigating the effects of total 
knee replacement on the markers of inflammation, endothelium and coagulation. This 
showed that all variables (except CD1442a) showed a significant change at all three 
time points following total knee replacement. The only exceptions to these were the 
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changes in e-selectin from day 1 to day 7, C-reactive protein from day 1 to day 7 and 
IL6 levels from pre-operative to day 7. 
  
No direct comparison to any current literature is possible as although there has been 
smaller studies looking at some of these changes in heterogeneous cohorts. Cruickshank 
et al (41) looked at other surgical procedures as well as total hip arthroplasty and found 
a correlation between the IL-6 response and the duration as well as the severity of the 
surgical trauma. In our cohort all patients were operated on by one of four consultant 
surgeons all using the standard approach and the same instrumentation with no 
significant variation in surgical operating time. Other studies have looked at changes in 
the IL-6 response following total knee arthroplasty. Lisowska et al in 2009 studied 40 
patients all with a history of rheumatoid arthritis undergoing total knee arthropasty 
(228). Their study comprised of 35 females and 5 males with an average age of 58.9 +/- 
8.5 years. All subjects received a spinal anaesthetic and a tourniquet was used. Venous 
samples were taken pre-operatively and up to 36 hours post-operatively. They showed 
significant rises in both the IL-6 and CRP responses with CRP peaking at 36 hours but the 
IL-6 response not being significant at 36 hours. Our study differs in that samples were 
taken at day 7 post-operatively with the CRP levels remaining significantly raised at day 
7 and with a continued significant rise from day 1 to day 7 of the IL-6 levels. The 
authors did also state in their results that they could find no correlation between the 
tourniquet time and the IL-6 and CRP response. There was no mention of whether bone 
cement was used or not. Our results support that of Honsawck et al in 2011 who looked 
at the IL-6 and CRP response following cemented total knee arthroplasty (229). All 
patients (n=49) had either a general or spinal anaesthetic with a post-operative drain 
used for 24 hours afterwards. Venous samples were taken pre and post-operatively as 
well as at 2, 6, 14 and 26 weeks later. They found that it took up to 2 weeks for the 
levels to return to their pre-operative levels. 
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Hughes et al undertook a small study of only 10 patients (mean age 77) in 2010, this 
comprised of mxture of 5 total knee and 5 total hip arthroplasties (230). All patients 
underwent a general anaesthetic and had venous blood sampling up to day 5 post-
operatively. They demonstrated significant rises in both groups with regards to the 
white cell count which peaked after 24 hours and returned to baseline at day 5 
(p<0.05). Whereas in our sample the white cell count levels remained significantly 
elevated at day 7 (p=0.01). This correlates with a study by Defi et al who studied 24 
patients (19 females; 5 males) undergoing a total hip arthroplasty with sampling up to 1 
week post-operatively (231). They demonstrated significant rises in both the white cell 
count and CRP levels up to 1 week post-operatively  The neutrophil count rose 
significantly at day 3 in the hip arthroplasty group (p<0.05) and at day 1 in the knee 
arthroplasty group (p<0.05) with levels returning to baseline at day 5. The monocyte 
and VWF levels did not show a significant change in the hip arthroplasty group and 
peaked at day 1 and day 3 respectively in the knee arthroplasty group, again returning 
to baseline levels at day 5.  Both the neutrophil, monocyte and VWF levels in our study 
remained significant up to day 7. Hughes et al also conducted a similar albeit shorter 
study looking at upper limb surgery in 2010 (232) (n=10). Samples were taken for both 
CRP and VWF levels but only up to 15 minutes post-procedure. They demonstrated a 
significant rise in the CRP levels only (p<0.05). 
 
Pape et al in 2000 looked at a heterogeneous group ranging from polytrauma to ankle 
fixation (227) and found that a significant rise in TNFα following femoral nailing but not 
in total hip arthroplasty. In his conclusion he stated that he was not able to comment on 
the effect of the bone cement on the markers measured in his study. Due to a limitation 
of resources we were unable to carry out the TNFα analysis on the local anaesthetic and 
surgical drain group but they were carried out in the cemented and uncemented group 
with the uncemented group demonstrating a significant change at day 7. This correlates 
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with a study by Reikeraas et al in 2005 who studied 7 patients (4 female; 3 male) 
undergoing and uncemented total knee arthroplasty. Samples were taked up to day 6 
post-operatively. They demonstrated significant changes on the TNFα levels up to day 6. 
 
Krohn et al (1999) also looked at changes to the TNFα levels following thoracic spinal 
surgery (n=8), 6 females; 2 males with a mean age of 15 (233). He found that TNFα 
levels significantly increased in the blood sampling but did not show a significant rise in 
the drained blood. He also showed that the levels of IL-6 in the drained blood were of a 
greater concentration (by the order of 10) compared to the levels in the venous blood. 
This has been reflected in other studies such as the one by Arnold et al (1995) who 
measured the IL-6 levels in the wound drainage blood following total hip arthroplasty 
(n=10) (234), he also showed significant levels  of IL-6 in the wound drainage blood. 
Bastian et al also found that levels of both IL-6 and TNFα in the wound drainage blood 
was significantly higher than the levels found systemically (n=7) in those undergoing a 
total hip replacement (235).  
 
Other studies have demonstrated significant changes in t-PA levels following total hip 
arthroplasty, this is the first study to confirm that similar changes also occur following 
total knee arthroplasty (219).Our results correlate with that of Kageyama et al (226) 
who showed a significant expression of CD40 as well as correlation with sCD40L 
following total knee arthroplasty. His paper did highlight the possible effect of the use 
of a tourniquet but the numbers involved were too small. All our subjects were 
operated on by consultants with an operating time ranging from sixty to ninety minutes 
with no significant variation in the operating time between all four groups. A pneumatic 
tourniquet was used for all subjects. There has been some evidence to suggest that the 
use of a tourniquet induces blood hypercoagulability due to the retention of blood flow 
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and disorders of the vascular endothelium (216-218). The potential ‘effect’ of the 
tourniquet has been negated by the fact that all the subjects in the studies had a 
tourniquet but the possible effects that its use may have had on the results cannot be 
assessed or quantified.  
 
Currently there are no published studies to compare our findings as regards the sCD40L 
changes seen following total knee arthroplasty. There have been studies into sCD40L but 
not in orthopaedics. Antoniades et al found that in coronary bypass graft surgery the 
pre-operative levels of sCD40L were predictive of the chances of developing post-
operative atrial fibrillation (236) in 144 patients. Desideri et al conducted an 
observational prospective study of 300 patients over 24 months following haemodialysis 
and found that higher levels of sCD40L were associated with a significant risk of 
cardiovascular morbidity and mortality (237) 
 
The strength of our studies are the fact that they were all conducted in a single centre. 
All the operations were undertaken by one of four surgeons using the same basic 
approach and instrumentation. There was no significant difference in the tourniquet or 
operating time and the blood sampling was undertaken as per protocol. The potential 
weaknesses are the unknown effect that the tourniquet may have had on the study 
results. As some of the variables had a short half-life significant changes may have been 
missed as the first sampling following the operation was taken 24 hours later. Also the 
patients in this study were operated on by one of four surgeons with surgeons operating 
on patients from each of the 4 study groups. The effect that this may have on the 
results is difficult to quantify but with all four surgeons using the standard approach 
with the same instrumentation and same knee prosthesis this would minimize the 
potential impact of this. 
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In conclusion these studies demonstrate that total knee arthroplasty results in the 
activation of common markers of inflammation, endothelium and coagulation. These 
changes may explain the increased incidence of venous thrombosis and 
thromboembolism post-operatively as well as a potential increased risk of arterial 
thrombosis and sequelae from atherosclerotic plaque rupture. 
 
 
8.2 Future direction 
 
Future research would be needed to further investigate these issues. This would involve 
a single centred randomized large cohort study involving just one surgeon. To fully 
assess the potential effect of the tourniquet a large study group would be needed which 
would be randomized into either a with or without tourniquet group performed by the 
one surgeon. If this did not show a significant difference then this group as a whole 
could be compared to a second single surgeon group undergoing a cemented total knee 
arthrplasty group to assess the effects of the bone cement on the markers of 
inflammation, coagulation and of endothelial dysfunction. If however a difference is 
demonstrated by the use of the tourniquet then a single surgeon study would be needed 
with randomization into either a cemented or uncemented total knee arthroplasty with 
no tourniquet. 
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ANNEX 1 
 
Participant Information Sheet  
 
NON-INVASIVE MARKERS OF ENDOTHELIAL FUNCTION IN ADULTS 
UNDERGOING TOTAL KNEE REPLACEMENT  
 
 
You are being invited to take part in a research study.  Before you decide, it is important that you 
should understand why this research is being done, and what it will involve.  Please take time to read 
this information sheet and to discuss it with family or friends if you wish.  Please ask about anything 
you are not clear about or do not understand. 
 
What is the purpose of the study? 
 
The main purpose of the study is to examine the effects of joint replacement on blood vessels. It is 
already known that a small number of people who present with broken bones or undergo joint 
replacement are at risk of developing some complications after their operation like heart disease or 
stroke. Inflammation in the blood vessels may contribute to these problems. This study aims to look at 
whether joint replacement may cause inflammation in blood vessels. 
 
Why have I been chosen? Do I have to take part? 
 
You have been invited to take part because you are undergoing a total knee replacement. The decision 
to take part or not is entirely up to you.  If you do decide to take part, you are free to withdraw at any 
time. 
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What does the study involve? 
 
You will be asked to sign the consent form attached to this Information Sheet.  Some of your medical 
details will be discussed with you to ensure that you are eligible for the study.   
 
At the pre-assessment clinic at the same time as your routine blood samples are being taken some 
additional blood tubes will be collected so that no additional needles are needed. The total amount of 
extra blood collected will be about 30ml (six teaspoonfuls) of blood.  In addition to this you will also 
undergo a tracing of your heart (otherwise known as an ECG) and a test of the blood vessels in your 
arms and legs (otherwise known as ABPI). The ABPI test involves measuring the blood pressure in all 
your arms and legs.  
At days number 1 and 7 after your operation, again whilst you are getting your normal bloods checked 
we shall also take off another 30 mls of blood.   
 
 
What are the risks or side effects of taking part? 
 
There are no foreseeable risks.  Blood will be taken, which would be taken anyway.  
 
What are the possible benefits of taking part?  Will I be paid? 
 
If the tracing of your heart or the test of the blood vessels in your arms/legs reveals any abnormalities 
we shall refer you onto the appropriate specialists.  
 
You will not be paid for taking part in the study. 
 
Confidentiality 
 
If you decide to take part in this study, we will inform your GP.  This is so that all doctors involved in 
your care are fully informed. Otherwise, no information about you will leave the Department of 
Orthopaedics. Confidential records will be kept secure. 
 
A scientific paper will be prepared using results from the study, and it is likely that this will be 
published in a medical journal.  You will not be identifiable from any report. 
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Who is organising and funding this research? 
 
The chief investigator is Mr Alec Campbell of the Department of Orthopaedics at Monklands 
Hospital, using research funds belonging to the Department  
 
Further information 
 
You can discuss this study with the clinical investigator who will be carrying out the study: 
 
Mr Kenneth Cheng 
Department of Orthopaedics, 
Monklands Hospital,  
Airdrie 
Page 419 
 
You can speak to someone who is able to give independent advice about the study: 
 
Mr I McLeod, Consultant Orthopaedic Surgeon 
Department of Orthopaedics, 
Monklands Hospital,  
Airdrie 
01236-712-294 
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CONSENT FORM  
 
Title of Project:  NON-INVASIVE MARKERS OF ENDOTHELIAL FUNCTION IN ADULTS 
UNDERGOING TOTAL KNEE REPLACEMENT 
 
Names of Researchers: Mr A Campbell 
 Mr K Cheng 
  
 
              Please initial each statement 
 
1. I confirm that I have read and understand the information sheet dated      
18/06/07 for this study and have had the opportunity to ask questions. ____ 
 
2. I understand that my participation is voluntary and that I am free to withdraw   
 at any time without giving any reason, without my medical care or legal rights  
 being affected. ____ 
 
3. I understand that sections of any of my medical notes may be looked at by     
 responsible individuals from regulatory authorities where it is relevant to my 
taking part in research.  I give permission for these individuals to have access 
to my records. ____ 
 
4.   I understand that my general practitioner will be informed of my participation ____ 
  in this study 
 
5. I agree to take part in the above study. ____ 
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Name of Subject  Date  Signature 
 
 
      
Name of person taking consent  Date  Signature 
   (if different from researcher) 
 
      
Name of Researcher  Date  Signature 
 
 
1 for patient, 1 for researcher, 1 to be kept with hospital notes 
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ANNEX 2 
 
Department of Orthopaedic Surgery, 
Monklands Hospital, 
Monkscourt Avenue 
Airdrie 
ML6 0JS 
 
Dear Dr, 
 
For your information, the above patient has agreed to take part in a research study based here at the 
Department of Orthopaedics. I enclose a copy of the patient information sheet for your perusal. 
 
If you wish to discuss this further please feel free to contact me. 
 
 
Yours sincerely, 
 
 
 
 
 
Mr Kenneth Cheng 
Orthopaedic SpR 
Phone 07803203888 
E-mail: kennethcheng@nhs.net 
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ANNEX 3 
Lanarkshire Local Research Ethics Committee 
Lanarkshire NHS Board 
14 Beckford St 
Hamilton 
ML3 OTA 
 
Telephone: 01698 281313  
Facsimile:  
11 January 2008   
 
Mr A Campbell 
Consultant Orthopaedic Surgeon 
Monklands Hospital 
Monkscourt Avenue 
Airdrie 
 
Dear Mr Campbell 
 
Full title of study: Non invasive markers of endothelial function in adults 
undergoing total knee replacement 
REC reference number: 07/S1001/51 
 
Thank you for your letter responding to the Committee’s request for further information on the 
above research and submitting revised documentation.   
 
The further information has been considered on behalf of the Committee by the Chair.   
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Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised.   
 
Ethical review of research sites 
 
The favourable opinion applies to the research sites listed on the attached form.  
 
Conditions of approval 
 
The favourable opinion is given provided that you comply with the conditions set out in the 
attached document.  You are advised to study the conditions carefully. 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date      
Application  5.4  14 August 2007    
Investigator CV   2 January 2008   
Protocol  1  18 June 2007    
Covering Letter  1  14 August 2007    
Statistician Comments  1  09 August 2007    
GP/Consultant Information Sheets  1  18 June 2007    
Participant Information Sheet: PIS  1  18 June 2007    
Participant Consent Form: PCF  1  18 June 2007    
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R&D approval 
 
All researchers and research collaborators who will be participating in the research at NHS sites 
should apply for R&D approval from the relevant care organisation, if they have not yet done so.  
R&D approval is required, whether or not the study is exempt from SSA.  You should advise 
researchers and local collaborators accordingly. 
 
Guidance on applying for R&D approval is available from 
http://www.rdforum.nhs.uk/rdform.htm. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees (July 2001) and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National Research Ethics 
Website > After Review  
 
Here you will find links to the following 
a)   Providing feedback. You are invited to give your view of the service that you have received 
from the National Research Ethics Service on the application procedure. If you wish to 
make your views known please use the feedback form available on the website. 
b)   Progress Reports. Please refer to the attached Standard conditions of approval by 
Research Ethics Committees. 
c)   Safety Reports. Please refer to the attached Standard conditions of approval by Research 
Ethics Committees. 
d)   Amendments. Please refer to the attached Standard conditions of approval by Research 
Ethics Committees. 
e)   End of Study/Project. Please refer to the attached Standard conditions of approval by 
Research Ethics Committees. 
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We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referencegroup@nationalres.org.uk . 
 
 
07/S1001/51 Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
 
 
MRS. P. CONWAY 
SECRETARY TO THE GROUP 
 
 
 
Enclosures: Standard approval conditions [SL-AC1 for CTIMPs, SL-AC2 for other studies]  
Site approval form 
 
1 
 
Lanarkshire Local Research Ethics Committee 
 
LIST OF SITES WITH A FAVOURABLE ETHICAL OPINION 
For all studies requiring site-specific assessment, this form is issued by the main REC to the Chief Investigator and sponsor with the favourable opinion letter and 
following subsequent notifications from site assessors.  For issue 2 onwards, all sites with a favourable opinion are listed, adding the new sites approved. 
 
REC reference number: 
 
07/S1001/51 
 
Issue number: 
 
0 
 
Date of issue: 
 
11 January 2008 
Chief Investigator: Mr A Campbell 
 
Full title of study: 
 
Non invasive markers of endothelial function in adults undergoing total knee replacement 
This study was given a favourable ethical opinion by Lanarkshire Local Research Ethics Committee on 11 January 2008. The favourable opinion is extended to each 
of the sites listed below.  The research may commence at each NHS site when management approval from the relevant NHS care organisation has been confirmed. 
 
Principal Investigator 
 
Post 
 
Research site 
 
Site assessor 
 
Date of favourable 
opinion for this site 
 
 
Notes (1) 
2 
 
 
(1) The notes column may be used by the main REC to record the early closure or withdrawal of a site (where notified by the Chief Investigator or sponsor), the 
suspension of termination of the favourable opinion for an individual site, or any other relevant development.  The date should be recorded
Mr A Campbell Consultant Orthopaedic 
surgeon 
Monklands Hospital - 
NHS Lanarkshire 
Lanarkshire Local 
Research Ethics 
Committee 
11/01/2008  
Approved by the Chair on behalf of the REC: 
 
.……………………………………………… (Signature of Chair/Co-ordinator)  
(delete as applicable) 
 
………………………………………………. (Name) 
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